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ABSTRACT 
 
 
 The investigation of the differential roles GABAA receptor (GABAAR) subtypes 
play in mediating various behaviors such as fear and anxiety was an intriguing research 
topic over the past decade. At present, most evidence suggests that benzodiazepine (BZ)-
induced anxiolysis is primarily mediated by GABAARs containing the α2-subunit (α2-
subtype). However, there is conflicting evidence as to whether α1- and α3-subtypes might 
also be involved in BZ-induced anxiolysis. In an attempt to further discern the role 
played by different α-subtype GABAARs in BZ-induced anxiolysis both systemically and 
within the basolateral amygdala (BLA), a brain region crucial for anxiety-like behaviors, 
we examined the anxiolytic-like effects, as measured by elevated-plus maze test (EPM), 
of several subtype selective and non-selective GABAAR positive allosteric modulators 
(PAMs) both in wild type mice and in mutant mice that express BZ-insensitive 
GABAARs of specific α-subtypes.  
 
 In our experiments, systemic injections of the α1-selective PAM zolpidem in WT 
mice produced slight anxiolytic-like effects with a narrow therapeutic window that 
overlapped with prominent motor-inhibiting effects. Systemic injection of the α3-
selective PAM TP003 produced marked anxiolytic-like effects in WT mice that were 
accompanied by motor-stimulating effects. Systemic injection of the α2-, α3-, and α5-
selective PAM L-838417 elicited significant anxiolytic-like effects in WT, and the effects 
were weakened in the α3(H126R) mice. Similarly, anxiolytic-like effects were observed 
when these selective PAMs were administered via microinjection into the BLA; however, 
these local injections did not significantly affect motor activity at the doses tested. In the 
experiment examining systemic injections of the non-selective BZ chlordiazepoxide 
(CDP), we found that CDP induced robust anxiolytic-like effects in both male and female 
WT mice. These effects were potentiated in female α1(H101R) mice, and were reduced 
in α2(H101R) mice of both sexes, as well as male α3(H126R) mice. Interestingly, intra-
BLA microinjection of CDP produced few effects in WT, α1(H101R), or α2(H101R) 
mice, but showed some anxiolytic-like effects in α3(H126R) mice.  
 
 Taken together, our results suggests (i) all three (α1-, α2-, and α3-) GABAAR 
subtypes are involved in BZ-induced anxiolysis, but subtle differences do exist; (ii) 
augmentation of the α1-subtype GABAARs exerts anxiolytic-like effects; however, the 
therapeutic window is narrow; (iii) augmentation of the α2-, α3-, (and α5-) subtype 
GABAARs exerts anxiolytic-like effects and motor-stimulating effects, and these effects 
are weakened in α3(H126R) mice at doses tested, (iv) augmentation of the α3-subtype 
GABAARs exerts anxiolytic-like effects, accompanied by motor-stimulating effects; (v) 
BLA is an important brain region that is sufficient to mediate the anxiolytic-like effects, 
but not the motor-stimulating or inhibiting effects of subtype selective GABAAR PAMs; 
and (vi) intra-BLA microinjection of CDP yielded an inconclusive behavioral outcome, 
possibly due to the complex GABAergic intra-amygdaloidal microcircuitries which 
might antagonize each other when multiple subtypes of GABAARs are simultaneously 
modulated by BZs. Taken together, our results provide novel evidence that may benefit 
the current development of subtype selective drugs for treating clinical anxiety disorders.  
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CHAPTER 1.    INTRODUCTION 
 
 
Background 
 
 The neurotransmitter gamma-aminobutyric acid (GABA), initially identified in 
the brain circa 1950, is an key substance in mediating inhibitory neuronal functions 
(Curtis, Duggan, Felix, & Johnston, 1970; Enna, 2011; Roberts, 1974; Roberts & 
Frankel, 1950). There are three subcategories of GABA receptors, namely type A 
(ionotropic), type B (metabotropic), and a third type, sometimes referred to as type C 
(ionotropic) (Barnard et al., 1998). GABA type A receptors (GABAARs) are ligand-gated 
ion channels that mediate chloride (anion) currents which, under normal physiological 
conditions in adults, inhibits the neuron; although they might also mediate excitatory 
transmission especially during early development (Barnard et al., 1998; Cherubini, 
Gaiarsa, & Ben-Ari, 1991). GABAARs are pentameric receptors composed of unique 
combinations of receptor subunits, including, but limited to, α, β, γ, or δ subunits (Olsen 
& Sieghart, 2009; E. Sigel & Steinmann, 2012). Among them, α1β2γ2, α2β3γ2, and 
α3β3γ2 are by far the highest expressed BZ-sensitive subunit compositions in the brain 
(Whiting, 2003). The physiological response of GABAARs can be modulated by various 
substrates that bind to different binding sites on the receptor, such as benzodiazepines 
(BZs), ethanol, barbiturates, and neurosteroids (Olsen, 2015). GABAARs containing a α1-
, α2-, α3-, or α5-subunit positioned adjacent to the γ-subunit form a “BZ-site” that binds 
BZ-like ligands, which can modulate the activity of GABAARs (Möhler, Crestani, & 
Rudolph, 2001; Erwin Sigel, 2002). These receptors are often referred by which α-
subunits they contain in adjacent to the γ-subunit, e.g., α1-, α2-, α3-, or α5-subtype 
GABAARs. Positive modulation of GABAARs by BZs are known to mediate a plethora of 
pharmacological and behavioral effects, such as anxiolysis (reduction of anxiety), 
myorelaxation, sedation, amnesia, and seizure inhibition (Rudolph & Knoflach, 2011). 
Among them, the anxiolytic-like effects of the positive allosteric modulators (PAMs) of 
the BZ-site are of high significance in both clinical treatment of anxiety disorders and in 
basic neuroscience research (Atack, 2010a; Kalat, 2007; T. A. Smith, 2001). 
 
 During the last two decades, considerable evidence has revealed similarities and 
differences in the regional distribution and physiological functions of distinct GABAAR 
subtypes (Rudolph & Knoflach, 2011). At present, several studies have revealed that the 
α2-subtype GABAARs play a predominant role in BZ-induced anxiolysis (Low et al., 
2000; K. S. Smith, Engin, Meloni, & Rudolph, 2012). However, past studies have also 
revealed conflicting results concerning the involvement of α1- and α3-subtype GABAARs 
in anxiety, and have yet to distinguish the differential contribution of these subtypes. For 
example, past evidence suggested that selective antagonism of the α1-subtype GABAAR 
abolished the anxiolytic-like effects of systemic BZ treatment, supporting the 
involvement of α1-subtype in BZ-induced anxiolysis (Belzung, Le Guisquet, & Griebel, 
2000). Other studies using BZ-site point mutant mice that rendered them insensitive to 
BZs, [α1(H101R), α2(H101R), and α3(H126R)], indicated the anxiolytic-like effects of 
systemic BZ treatment are largely mediated by α2- rather than α1- or α3-subtype (Low et 
al., 2000; K. S. Smith et al., 2012). Still, other independent studies found that systemic 
 2 
injection of the α3-selective PAM TP003 produced anxiolytic-like effects while systemic 
administration of the α3-selective inverse-agonist Alpha3IA caused an anxiogenic-like 
behavioral profile, supporting the possibility that α3-subtype also mediate BZ-induced 
anxiolysis (Atack et al., 2005; Dias et al., 2005).  
 
 BZ-sensitive GABAARs are located in a number of brain regions known to play 
roles in mediating behaviors indicative of anxiety, including the hippocampus, amygdala, 
and bed nucleus of stria terminalis (Pirker, Schwarzer, Wieselthaler, Sieghart, & Sperk, 
2000). Among them, the basolateral amygdala (BLA) is a particularly crucial brain region 
involved in the control of anxiety and fear-related behaviors, and is densely populated 
with BZ-sensitive GABAARs (M. Davis, 2000; File, 2000; LeDoux, 2000; Pirker et al., 
2000). It receives various sensory inputs and sends processed information to the central 
amygdala (CeA), which is a main output nucleus controlling the downstream brain 
regions that contribute to fear/anxiety responses (Janak & Tye, 2015; Lee, Kim, Kwon, 
Lee, & Kim, 2013; Sah, Faber, Lopez De Armentia, & Power, 2003). Animal studies 
showed that non-selective BZs produce anxiolytic-like effects when injected directly into 
the BLA (McNamara & Skeleton, 1993; Menard & Treit, 1999; Pesold & Treit, 1995). 
However, it is currently unclear whether these anxiolytic-like effects are mediated by the 
action of BZs on particular α1-, α2- or α3-subtypes, or whether all subtypes act 
synergistically to reduce anxiety.  
 
 In this study, we utilized both the point mutant mice and the subtype selective 
GABAAR PAMs to investigate the differential roles of α1-, α2- and α3-subtypes in BZ-
induced anxiolysis after systemic injections. Further, we locally delivered the drugs to the 
BLA to test whether BLA is a crucial brain area mediating the anxiolytic-like effects 
found in global positive modulation of GABAAR by systemic injection. Our overall goal 
is to assess and discern the differential contributions of α1-, α2- and α3-subtypes in 
mediating BZ-induced anxiolysis, both systemically and within the BLA. 
 
 
Clinical Significance 
 
 The acute use of classic non-selective BZs is effective in reducing anxiety in 
humans. However, long-term use of BZs as an anxiolytic treatment can result in the 
development of tolerance and dependence, among many other side effects (Stevens & 
Pollack, 2005). Some evidence suggests that α1-subtype GABAARs mediate the 
undesirable addictive properties of BZs (Rudolph & Knoflach, 2011; Tan et al., 2010). A 
α1-subtype selective GABAAR PAM, zolpidem, also causes motor-impairing and 
amnesic side effects in animal studies (Cope et al., 2004; Zanin et al., 2013), further 
reviewed in (Fitzgerald, Wright, & Heldt, 2014). Thus, developing subtype selective 
anxiolytics that have little affinity or efficacy to α1-subtype is promising (Atack, 2005).  
 
 In addition to BZs, selective serotonin reuptake inhibitors (SSRIs) that inhibit 
serotonin reuptake and augment synaptic serotonin levels are also effective in reducing 
anxiety; however, anxiolytic-like effects only develop following chronic, but not acute 
treatment. In fact, acute SSRI treatment actually increases fear and anxiety responses in 
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both human as well as in laboratory animals (Burghardt, Sullivan, McEwen, Gorman, & 
LeDoux, 2004; Grillon, Levenson, & Pine, 2007; Pettersson, Naslund, Nilsson, Eriksson, 
& Hagsater, 2015). The acute anxiogenic profile makes the usage of SSRI 
disadvantageous in cases where anxiety symptoms need to be managed acutely 
(Burghardt et al., 2004). Taken together, although classic non-selective BZs are suitable 
for acute treatment of anxiety disorders, their tolerance properties and side effects render 
them far from ideal for chronic anxiety management. Conversely, although SSRIs are 
effective in chronic treatment settings, they are disadvantageous for situations where 
anxiety symptoms needs to be managed acutely. This makes the development of novel 
subtypes-selective GABAAR PAMs that retain the efficacy in anxiolysis but with their 
side effects minimized a promising venue for improving the existing pharmaceutical 
treatment options for anxiety disorders (Rudolph & Knoflach, 2011).  
 
The purpose of the present study is to differentiate between the contributions of α1-, α2- 
and α3-subtype GABAARs to BZ-induced anxiolysis. Our work will clarify not only the 
general involvement of α-subtypes in BZ-induced anxiolysis but also reveal whether 
positive modulations of different α-subtypes in the BLA participate in the induction of 
anxiolysis. Our results may provide important evidence useful for the development of 
novel subtype selective drugs for the treatment of clinical anxiety disorders. 
 
 
Overview of Experimental Design 
 
 
Systemic Injection of Selective GABAAR PAMs 
 
 We examined the presence (or absence) of anxiolytic-like effects elicited by 
systemic administration of selective PAMs of α1-, α2- and/or α3-subtype GABAARs. To 
achieve this, we assessed the anxiety-like behaviors using the EPM after selective 
positive modulation of α1-, α2-, and/or α3-subtypes pharmacologically via systemic 
injection of the following compounds: (i) Zolpidem, a α1-selective GABAAR PAM; (ii) 
TP003, a α3-selective GABAAR PAM; (iii) L-838417, a partial PAM for the α2-, α3-, 
and α5-subtypes (McKernan et al., 2000), was administered to α3(H126R) mice 
expressing BZ-insensitive α3-subtype GABAARs. The latter approach (iii) was employed 
as we were unable to obtain a reliable α2-selective GABAAR PAM. Thus, a combination 
of selective drug and point mutant mice was used. The Ki value of L-838417 to α5-
subtype GABAARs was ~3 times as high as that of α2- and α3-subtypes in a radioligand 
binding assay, although the efficacy of L-838417 at α5-subtype GABAARs was 
comparable to that of α2- and α3-subtypes (McKernan et al., 2000). Since the α5-subtype 
GABAARs have a much lower expression profile in the whole brain when compared to 
α1-, α2, and α3-subtypes (Whiting, 2003), and are considered non-essential in mediating 
BZ-induced anxiolysis (Collinson et al., 2002), we argue that the anxiolytic-like effect 
seen in this experiment should be predominantly due to the selective positive modulation 
of α2-subtype GABAARs.  
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Systemic Injection of Non-selective BZ 
 
 We examined the presence (or absence) of anxiolytic-like effects elicited by 
systemic administration of non-selective BZ to animals where a specific α-subtype was 
rendered BZ-insensitive. We tested whether the anxiolytic-like effect of systemic BZ 
treatment was blunted in α1(H101R), α2(H101R) or α3(H126R) mice as measured by the 
EPM. A similar line of study was previously conducted (K. S. Smith et al., 2012). We 
extended that study by including female subjects in our experiment and examining 
whether the anxiolytic-like effects of systemic BZ treatment are sex-dependent.  
 
 
Intra-BLA Microinjection of Selective GABAAR PAMs 
 
 Since the BLA is known to be a crucial brain region in mediating anxiety-like 
behaviors and anxiolytic-like effects of BZs (M. Davis, 2000; Green & Vale, 1992; Heldt 
& Ressler, 2006; Pesold & Treit, 1995; Sanders & Shekhar, 1995), we examined the 
presence (or absence) of anxiolytic-like effects elicited by administration of selective 
positive modulators of α1-, α2- and/or α3-subtype GABAARs within the BLA. To 
achieve this, we assessed the anxiety-like behaviors using the EPM after administration 
of subtype selective pharmacological agents via intra-BLA microinjection. Mice were 
tested for anxiety-like behaviors after intra-BLA administration of one of the following 
drug treatments: (i) Zolpidem, a α1-selective GABAAR PAM; (ii) TP003, a α3-selective 
GABAAR PAM; (iii) a combination of selective drug, L-838417, and point mutant mice, 
α3(H126R), was used to achieve selective positive modulation of the α2- and α5-
subtypes, as described in an earlier section. Since the expression of α5-subtype is low in 
the amygdala compared to α1-, α2- and α3-subtypes (Fritschy & Mohler, 1995; 
Mathiasen, Rodgers, & Mirza, 2007; Pirker et al., 2000), the effects seen should be 
predominantly due to the positive modulation of α2-subtypes.  
 
 
Intra-BLA Microinjection of Non-selective BZ 
 
 We also examined the presence (or absence) of anxiolytic-like effects elicited by 
intra-BLA administration of non-selective BZ in animals where a specific α-subtype was 
rendered BZ-insensitive. To achieve this, we investigated whether the anxiolytic-like 
effects of intra-BLA microinjection of BZ were blunted in α1(H101R), α2(H101R) or 
α3(H126R) mice as measured by the EPM. 
 
 The current view that α2-subtype GABAARs are necessary for mediating BZ-
induced anxiolysis comes from studies showing that the anxiolytic-like effects of BZ 
were ablated in point mutant mice with BZ-insensitive α2-subtype GABAARs, as 
assessed by the EPM (Low et al., 2000; K. S. Smith et al., 2012). In our experiments, we 
used the combination of subtype selective drugs and point mutant mice to gain further 
insights into the differential roles α1-, α2-, and α3-subtype GABAARs play in anxiety and 
BZ-induced anxiolysis.  
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CHAPTER 2.    LITERATURE REVIEW 
 
 
Clinical Aspects of Anxiety Disorders 
 
 Anxiety disorders are common psychiatric conditions with a 28.8% lifetime 
prevalence among U.S. adults and cause significant economic burden to both patients and 
society (Kessler et al., 2005; Kessler & Greenberg, 2002). They are an umbrella of 
several specific disorders, including, but not limited to, generalized anxiety disorder, 
phobias, and panic attacks (American Psychiatric Association, 2000). Normal levels of 
anxiety and fear are essential for vigilance and adaptation towards a threat uncertainty, 
and dissipate quickly when signals that indicate safety arise. However, pathological 
anxiety and fear during the interpretation and response towards threat uncertainty are 
maladaptive and can cause suffering of the subject (Grupe & Nitschke, 2013).  
 
 Anxiety disorders can be managed by both psychotherapy and pharmacotherapy 
in the clinic. Various modalities of psychotherapy were developed or adapted to treat 
anxiety disorders with promising effectiveness, such as cognitive behavioral therapy and 
interpersonal psychotherapy (Graham & Milad, 2011; Markowitz, Lipsitz, & Milrod, 
2014). Several lines of pharmacotherapy options are also available, such as 
antidepressant (SSRIs and SNRIs), azapirones, and benzodiazepines (Chessick et al., 
2006; Farach et al., 2012; Katzman et al., 2014; Reinhold & Rickels, 2015). However, 
these traditional treatment options have several limitations, such as significant side 
effects, or prolonged delay before the onset of efficacy, see the "Clinical Significance" 
section in Chapter 1. 
 
 
Animal Models for Assessing Fear and Anxiety-like Behaviors 
 
 The terms “fear” and “anxiety” co-occur very often in the literature and are 
indeed deeply intertwined with each other (Suinn, 1969). In recent years, the distinctive 
differences between anxiety and fear have become increasingly recognized from both 
behavioral and neural circuitry points of view, and the different but overlapping 
underlying neural circuitries are being elucidated (M. Davis, Walker, Miles, & Grillon, 
2010; Perusini & Fanselow, 2015; Tovote, Fadok, & Lüthi, 2015). In animals, the 
predatory imminence theory provides an accepted distinction between fear, and anxiety 
(Perusini & Fanselow, 2015). 
 
 To study the neurological basis of anxiety and fear, researchers have long used the 
behaviors of animals as models of these complex human emotions. To validate an animal 
behavioral paradigm as a tool to study the emotion of fear and anxiety, face validity 
(whether the test appears to measure the emotion), construct validity (whether the 
parameter collected reflects the underlying emotion), as well as predictive validity 
(whether the test can predict other measures of the emotion) must be met, although these 
standards are evolving (Belzung & Lemoine, 2011; Walf & Frye, 2007; Willner, 1984). 
In animals, the anxiety-like and fear-like behaviors are usually measured by their 
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responses to either (i) a potential, non-specific threat, such as exposure to an open space; 
(ii) a specific, but unconditioned threat, such as exposure to a predator odor; or (iii) a 
specific, conditioned, but non-imminent cue, such as an environmental context which is 
experimentally associated with a distinctive aversive stimulus, or (iv) a specific, 
conditioned, and imminent cue which is experimentally associated with a distinctive 
aversive stimulus, e.g. (Goosens & Maren, 2001; Wilson & Junor, 2008). Further, stress-
induced behavioral alterations and social interaction tests are also commonly used (File & 
Hyde, 1979; Fuchs & Fliugge, 2006; Zethof, Van der Heyden, Tolboom, & Olivier, 
1995).  
 
 In rodents, anxiety-like behaviors are assessed by behavioral paradigms such as 
open field, EPM, light dark box, defensive burying test, social interaction test, and stress-
induced hyperthermia test. Conversely, fear-like behaviors are typically assessed 
following a training session where punishing stimuli are delivered, such as Pavlovian 
conditioning paradigms (Adriaan Bouwknecht, Olivier, & Paylor, 2007; Bailey & 
Crawley, 2009; Blanchard, Griebel, & Blanchard, 2003; Curzon, Rustay, & Browman, 
2009; M. Davis, 1993; File, 1980; Njung'e & Handley, 1991; Pellow & File, 1986).  
 
 In animals, experimental exposures to stressful or aversive stimuli, brain lesions, 
and genetic / pharmacological manipulations can produce excessive fear and anxiety-like 
behaviors which serve as models of pathological conditions in humans. It is reported that 
stressful events, such as immobilization, maternal separation, and social defeat might lead 
to heightened state of anxiety in rodents (Huang et al., 2015; Kedia & Chattarji, 2014; 
Romeo et al., 2003). Recent study also reveals that mice display an elevated state of fear 
and anxiety following exposure to closed-head mild traumatic brain injury (Heldt et al., 
2014). These models are particularly useful in mimicking various clinical conditions 
where pathological anxiety is induced by a known stressor.  
 
 In this study, we used the EPM test, a validated behavioral paradigm to measure 
anxiety in rodents (Pellow & File, 1986; Walf & Frye, 2007), to study the differential 
anxiolytic-like effects of various GABAAR PAMs and the differential contributions of 
α1-, α2-, and α3-subtype GABAARs to anxiety-like behaviors.  
 
 
Brain Areas and Neurotransmitters Involved in Fear and Anxiety 
 
 Brain areas and their associated neurocircuitries that mediate fear and anxiety are 
highly conserved across a wide range of species (Adolphs, Tranel, Damasio, & Damasio, 
1995; Davies, Martinez-Garcia, Lanuza, & Novejarque, 2002; Janak & Tye, 2015). This 
is not surprising when considering the evolutionary importance of adaptive fear and 
anxiety in the survival of most species (Marks & Nesse, 1994; Ohman & Mineka, 2001; 
Price, 2003). While many brain regions participate in the generation and modulation of 
fear and anxiety behaviors, the amygdala, bed nucleus of the stria terminalis (BNST), 
hippocampus, hypothalamus, periaqueductal grey (PAG), and prefrontal cortex are well 
recognized as playing important roles in these processes (Avery, Clauss, & Blackford, 
2015; Bishop, Duncan, Brett, & Lawrence, 2004; Graeff, 2007; Graeff, Silveira, 
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Nogueira, Audi, & Oliveira, 1993; Tovote et al., 2015). These regions are admittedly not 
exclusively involved in fear and anxiety processes and both past and continued research 
recognizes that other brain areas, such as the lateral septum, also participate in these 
processes (Anthony et al., 2014).    
 
 The precise balance of neurotransmitter release in these brain areas is critical for 
their normal functions, e.g. (Gao et al., 2014; Prager, Bergstrom, Wynn, & Braga, 2015). 
Over the past few decades, a number of neurotransmitters have been identified to be 
involved in mediating fear and anxiety, including but not limited to, GABA, serotonin, 
norepinephrine, neurosteroids, and acetylcholine (Charney, Heninger, & Breier, 1984; 
Feighner & Boyer, 1989; File, Gonzalez, & Andrews, 1998; Hoehn-Saric, 1982; 
Kavaliers, Wiebe, & Galea, 1994). The roles these neurotransmitters and their receptors 
play in mediating anxiety and fear within the amygdala, BNST, and hippocampus are of 
great interest and are reviewed in the following sections.  
 
 
Amygdala 
 
 The amygdala complex is often divided into three major subdivisions: the 
basolateral amygdala (BLA), the central nucleus (CeA), and the medial nucleus (MeA) 
(Butler et al., 2012). Sensory input from cortical and thalamic regions converge to the 
BLA. In turn, the BLA sends efferent projections to separate subdivisions of the CeA and 
further project to various brain regions including the hypothalamus and the PAG (Janak 
& Tye, 2015).  
 
 Amygdalar structure and fear / anxiety 
 
 In humans, damage to the BLA results in impairments in conditioned fear 
acquisition and fear recognition, as well as decreases in levels of anxiety (Adolphs et al., 
2005; Dellacherie, Hasboun, Baulac, Belin, & Samson, 2011; Klumpers, Morgan, 
Terburg, Stein, & van Honk, 2015). Currently, there is limited evidence available 
regarding the impact of specific focal lesions of the CeA in human; although, it is 
reported that the impairments in fear recognition are comparable between humans with 
complete unilateral amygdala damage and unilateral BLA damage that spares the CeA 
(Dellacherie et al., 2011).  
 
 Most evidence revealing the role the amygdala plays in fear and anxiety comes 
from animal studies. Lesions of the CeA in adolescent rhesus monkeys resulted in the 
suppression of fear expressions when they were confronted with potentially threatening 
stimuli (Kalin, Shelton, & Davidson, 2004), although neonatal amygdalar lesions resulted 
in an impaired but not abolished fear response in macaques, suggesting that although 
amygdala is an important structure for mediating fear response, other parallel pathways 
also exist during development (Kazama, Heuer, Davis, & Bachevalier, 2012). Lesions of 
the BLA in rats lead to impaired conditioned avoidance, but left intact behavioral 
suppression response to the conditioned aversive stimulus, while CeA lesions resulted in 
reduced conditioned behavioral suppression, but left intact conditioned avoidance, 
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suggesting a marked distinction between the contribution of BLA and CeA to fear 
response (Killcross, Robbins, & Everitt, 1997). More recent studies showed that both 
lateral amygdala and CeA lesions, as well as disconnection between the two regions, 
resulted in deficits in fear processing and conditioned suppression (Campese, Gonzaga, 
Moscarello, & LeDoux, 2015). Lesions of the CeA in rats resulted in reduction of stress-
induced anxiety as measured by the EPM, as well as both contextual and cued-fear in a 
fear conditioning paradigm (Möller, Wiklund, Sommer, Thorsell, & Heilig, 1997; 
Sullivan et al., 2004; Ventura-Silva et al., 2013). Lesion of the MeA or BLA in mice also 
lead to reduction of anxiety (Wang, Zhao, Liu, & Fu, 2014). These studies suggested an 
indispensable and complex role of amygdala in mediating fear and anxiety-like 
behaviors. 
 
 In addition to classic lesion studies, the use of advanced circuitry mapping 
approaches, such as optogenetics (Boyden, 2011; Boyden, Zhang, Bamberg, Nagel, & 
Deisseroth, 2005), has added to the growing evidence supporting the key role the 
amygdala plays in mediating fear and anxiety. Overall, non-selective activation of BLA 
somata resulted in an anxiogenic outcome (Tye et al., 2011). On a projection-specific 
level, it is reported that optogenetic activation of the BLA to medial prefrontal cortex 
(mPFC) projection resulted in elevated anxiety-like behaviors while optogenetic 
inhibition of the pathway resulted in anxiolytic-like outcomes (Felix-Ortiz, Burgos-
Robles, Bhagat, Leppla, & Tye, 2015). Similar behavioral effects of optogenetic 
manipulation on social interaction were also found upon stimulating or inhibiting the 
BLA to ventral hippocampus projection (Felix-Ortiz & Tye, 2014). However, it is 
reported that optogenetic activation of the BLA to anterodorsal BNST projection, as well 
as the BLA to CeA projection, elicited anxiolytic-like effects (Kim et al., 2013; Tye et al., 
2011). These studies suggested that although the net output of BLA projection likely 
produces an anxiogenic profile, the projections from BLA to different brain areas have 
distinct and, in some cases, opposite effects.  
 
 Amygdalar GABAergic signaling and fear / anxiety 
 
 The pivotal role amygdala plays in anxiety and fear is also supported by 
numerous pharmacological studies that employed local manipulation of various 
neurotransmitters and receptors. For example, intra-BLA microinjection of BZs elicited 
anxiolytic-like effects, whereas intra-BLA microinjection of GABAAR antagonists 
produced an anxiogenic-like outcome (M. Davis, 2000; Green & Vale, 1992; Heldt & 
Ressler, 2006; Pesold & Treit, 1995; Sanders & Shekhar, 1995). Intra-CeA 
microinjection of midazolam elicited anxiolytic-like effects as measured by the shock-
probe burying paradigm but not the EPM. Thus, the anxiolytic-like effects of BZ 
manipulation in the CeA appeared to be task-dependent (Pesold & Treit, 1995). Other 
studies reported that microinjections of the GABAAR agonist muscimol into the CeA, 
rather than the BLA, produced anxiolytic-like effects as measured by the EPM (Moreira, 
Masson, Carvalho, & Brandão, 2007). The results from these two studies suggested 
differential effects of benzodiazepines (GABAAR positive allosteric modulators) versus 
muscimol (GABAAR agonist) when microinjected to the BLA. Taken together, these 
studies suggested that GABAergic neurotransmission in the amygdala mainly inhibits 
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fear and anxiety. However, at present, the effects of microinjection of GABAAR subtype 
selective compounds in the amygdala remains largely unclear due to limited supporting 
evidence.  
 
 A number of subpopulations of GABAergic interneurons reside in the amygdala 
complex. They can be divided roughly into the following three groups: a parvalbumin-
positive population, a cholecystokinin-positive population, and a somatostatin-positive 
population (Spampanato, Polepalli, & Sah, 2011 ; Wolff et al., 2014). It is reported that 
both parvalbumin and somatostatin interneurons in the BLA are implicated in fear 
learning via an indirect parvalbumin-somatostatin-pyramidal neuron dis-inhibitory 
microcircuit (Wolff et al., 2014). Increased number of parvalbumin neurons was 
correlated with reduced anxiety-like behaviors in a study that investigated the effects of 
exposure to enriched environment (Urakawa et al., 2013). Another study showed that the 
paraventricular nucleus of the thalamus innervated the somatostatin interneurons in the 
lateral CeA and this pathway is implicated in the control of fear processing (Penzo et al., 
2015).  
 
 Other amygdalar neurotransmitters and fear / anxiety 
 
 Besides GABAergic signaling, many other neurotransmitters, such as dopamine 
and serotonin, are also implicated in anxiety and fear-like behaviors in the amygdala. A 
number of studies, reviewed by de la Mora: (de la Mora, Gallegos-Cari, Arizmendi-
Garcia, Marcellino, & Fuxe, 2010), showed that microinjection of a dopamine D1 
receptor agonist to the amygdala (both the BLA and the CeA) elicited anxiogenic-like 
effects while microinjection of a D1 receptor antagonist resulted in anxiolytic-like 
effects; further, microinjection of a D2-like receptor antagonist in the BLA resulted in 
anxiolytic-like effects while microinjection of a D2-like receptor antagonist in the CeA 
produced paradoxical, task-dependent anxiogenic / anxiolytic-like effects (Greba, 
Gifkins, & Kokkinidis, 2001; F.A. Guarraci, Frohardt, Falls, & Kapp, 2000; F. A. 
Guarraci, Frohardt, & Kapp, 1999; Lamont & Kokkinidis, 1998; Perez de la Mora et al., 
2012). A study found that dopamine interacted with GABAergic signaling by inhibiting 
GABA release from parvalbumin-positive interneurons in the BLA (Chu, Ito, Li, & 
Morozov, 2012; Pape, 2005). This finding offered a possible explanation for dopamine-
driven disinhibition of the amygdala and subsequent behavioral outcomes. Another 
important neurotransmitter, serotonin, also plays a role in regulating the function of the 
amygdala. A study employing a microdialysis approach suggested that serotonin 
concentration in the BLA complex was elevated during a conditioned fear test (Zanoveli, 
Carvalho, Cunha, & Brandao, 2009). In another study, administration of serotonin to the 
amygdala resulted in anxiogenic-like effects as measured by conflict test, whereas 
depletion of serotonin in the BLA resulted in anxiolytic-like effects as measured by a 
social interaction paradigm and reduced fear response in a conditioned fear test (Hodges, 
Green, & Glenn, 1987; Johnson et al., 2015). Thus, both dopaminergic and serotonergic 
neurotransmission in the amygdala mainly promote fear and anxiety. This is in contrast 
with studies showing anxiolytic-like effects after chronic, systemic SSRI treatment that 
augmented extracellular serotonin level over a prolonged period of time (Abuhamdah, 
Hussain, Chazot, & Ennaceur, 2015; Dulawa, Holick, Gundersen, & Hen, 2004). 
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However, considering the studies that showed acute systemic SSRI treatment indeed 
promotes fear and anxiety-like behaviors both in rodents as well as in humans (Burghardt 
et al., 2004; Grillon et al., 2007), it is plausible that chronic enhancement of serotonergic 
transmission in the amygdala might allow anxiolytic-like effects to develop.  
 
 Other neurotransmitters, such as neuropeptides and neurosteroids, are also 
involved in the physiological function of the amygdala that controls fear and anxiety. It is 
reported that microinjection of neuropeptide Y into the BLA, but not CeA, elicited 
anxiolytic-like effects as measured by a social interaction paradigm (Sajdyk, Vandergriff, 
& Gehlert, 1999). Knockdown of cholecystokinin peptide by shRNA in the BLA elicited 
anxiolytic-like effects as measured by the EPM (Del Boca, Lutz, Le Merrer, Koebel, & 
Kieffer, 2012). Microinjection of a neurosteroid, allopregnanolone, into the amygdala 
resulted in anxiolytic-like effects as measured by both EPM and a defensive burying task 
(Engin & Treit, 2007a). These findings indicated that there is complexity due to the 
multitude of neurotransmitters in the amygdala and prompted further investigation of 
neurochemical dysregulation in the amygdala in the context of fear and anxiety.  
 
 All of the abovementioned studies, ranging from lesion studies, optogenetic 
studies, pharmacological studies and behavioral studies, support the major role the 
amygdala plays in mediating fear and anxiety. It is also worth pointing out that due to 
multiple effects of various projections, microcircuitries, and neurotransmitters in the 
amygdala, it is particularly interesting to dissect out the molecular and cellular causes of 
these phenomena.  
 
 
Bed Nucleus of the Stria Terminalis 
 
 The bed nucleus of the stria terminalis (BNST) belongs to the extended amygdalar 
structure (Swanson & Petrovich, 1998) and receives prominent inputs from the amygdala. 
Similar to the CeA, which also receives direct projection from the BLA, the BNST gives 
rise to projections that target common downstream brain areas such as the hypothalamus, 
and has been implicated in behaviors such as stress responses and anxiety. However, 
unlike the CeA, which mediates fast expression of fear and anxiety, the BNST is thought 
to be an important player in the orchestration of slow onset, prolonged fear and anxiety 
responses (Dong, Petrovich, & Swanson, 2001; Haufler, Nagy, & Pare, 2013; Sakanaka, 
Shibasaki, & Lederis, 1986; Spencer, Buller, & Day, 2005; Walker, Toufexis, & Davis, 
2003) .  
 
 Lesions of the BNST resulted in selective impairment of contextual fear but not 
cued-fear, which was in contrast to CeA lesions that impaired both functions (Sullivan et 
al., 2004). Inactivation of BNST blocked defensive responses towards fox odor as well as 
alarm pheromones in rodents (Breitfeld et al., 2015; Fendt, Endres, & Apfelbach, 2003). 
These findings suggested that BNST is largely responsible for behavior responses to the 
environmental context.  
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 The role that the BNST plays in fear and anxiety is further elucidated by several 
optogenetics studies. Importantly, a study revealed that the two subdivisions of BNST 
showed opposite functions, in which activities in the oval BNST sub-nucleus increased 
anxiety and activities in the anterodorsal BNST sub-nucleus inhibited anxiety. Also, 
photostimulation of the BLA to anterodorsal BNST projection elicited anxiolytic-like 
effects as measured by the EPM test (Kim et al., 2013). It was reported that 
photostimulation of the glutamatergic BNST to ventral tegmental area (VTA) projections 
resulted in an anxiogenic-like outcome whereas photostimulation of the GABAergic 
BNST to VTA projections lead to anxiolytic-like outcome (Jennings et al., 2013). These 
results demonstrated how BNST is intertwined with other brain regions, such as the BLA 
and the VTA, to orchestrate the fine tuning of fear and anxiety-like behaviors.  
 
 GABAergic transmission is shown to be involved in mediating a number of 
physiological functions and behavioral outcomes in the BNST. A study reported that 
deletion of the α1-subunit of GABAARs in the corticotropin-releasing factor-positive 
(CRF+) neurons (CRF-α1 KO) resulted in an anxiogenic outcome, which could be 
rescued by intra-BNST microinjection of a CRF antagonist. Same study also showed that 
microinjection of the α1-subtype selective PAM zolpidem in the BNST elicited 
anxiolytic-like effects in WT but not CRF-α1 KO mice (Gafford et al., 2012). Further, 
norepinephrine signaling in the ventral BNST was shown to be crucial for fear responses 
towards fox odor in rodents. A study reported that the noradrenaline level in the ventral 
BNST was significantly increased in response to trimethylthiazoline exposure, and 
microinjection of clonidine, a α2-adrenergic agonist that lowers noradrenaline level, in 
the ventral BNST abolished fox odor induced fear potentiation (Fendt, Siegl, & Steiniger-
Brach, 2005). Further, sex hormones and neurosteroids are both implicated in modulating 
fear and anxiety-like behaviors in the BNST (Nagaya, Acca, & Maren, 2015; Toufexis, 
2007).  
 
 To sum up, the BNST constitutes an integral part of the extended amygdalar 
structure, and together with the BLA and CeA, they control a large range of emotional 
responses and exert interconnected and inter-balanced effects via multiple projections.  
 
 
Hippocampus 
 
 Hippocampal formation (short-hand as “hippocampus” in the following text) can 
be roughly divided into dorsal and ventral portions, and further subdivided into several 
fields, including cornus ammoni (CA)1, CA2/CA3, and dentate gyrus (DG) (Amaral & 
Lavenex, 2007). Studies have shown that lesions of the ventral hippocampus lead to 
impairment of normal expression of anxiety, and it is believed that while the dorsal 
hippocampus is mostly involved in memory processing, the ventral hippocampus is 
mostly involved in anxiety (Bannerman et al., 2003; Bannerman et al., 2004).  
 
 A recent optogenetic study revealed that the DG was differentially involved in 
anxiety versus fear. It was reported that the dorsal division was more involved in 
contextual fear encoding, whereas the ventral division was more involved in innate 
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anxiety, signifying the dissociation of the differential functional roles played by the intra-
hippocampal subdivisions (Fournier & Duman, 2013; Kheirbek et al., 2013). The 
connection from BLA to ventral hippocampus is also implicated in social anxiety (Felix-
Ortiz & Tye, 2014).  
 
 Intra-hippocampal microinjection of BZ, among many other compounds, such as 
certain serotoninergic agonists and neurosteroids, results in anxiolytic-like effects (Engin 
& Treit, 2007b). A recent study utilizing intra-BLA microinjection of subtype selective 
GABAAR ligands revealed that the anxiety-like behaviors were mediated by the α2-
subtype GABAARs in the ventral hippocampus, whereas fear memory processing was 
mediated by the α5-subtype GABAARs in the dorsal hippocampus (McEown & Treit, 
2013).  
 
 To sum up, the hippocampus is a complex structure with multiple functions. The 
ventral hippocampus is an important brain structure that receives input from the BLA and 
is implicated in anxiety-like behaviors, whereas the dorsal hippocampus is more involved 
in learning, memory and fear-related behaviors.  
 
 
The Differential Functional Roles of GABAAR Subtypes 
 
 Most attempts to determine the contribution of the α1-, α2-, α3-, and α5-subtypes 
GABAARs in mediating behaviors have come from studies examining the effects of 
classic BZs (such as diazepam, chlordiazepoxide, midazolam, etc.) and other BZ-like 
ligands (such as zolpidem, L-838417, and TP003). These compounds often differ in their 
affinity and efficacy for different α-subtypes, and those that display preferential affinity 
and/or efficacy towards particular α-subtypes are referred to as subtype selective drugs. 
In combination with the use of these GABAAR ligands and genetically modified mice 
(KO, point-mutants), past studies have elucidated various functional differences among 
different α-subtype GABAARs.  
 
 
The α1-subtype GABAARs 
 
 Currently, the role that α1-subtype GABAARs play in fear and anxiety is unclear. 
In mice, systemic injection of α1-subtype selective antagonists blocked BZ-induced 
anxiolysis as measured by the EPM, suggesting an important role of α1-subtype in 
mediating BZ-induced anxiolysis (Belzung et al., 2000). Likewise, in mice that express 
BZ-insensitive α1-subtype GABAARs, i.e. the α1(H101R) mice, BZ-induced inhibition of 
a conditioned fear response was abolished, suggesting that α1-subtype GABAARs are 
necessary for the effects of BZ on fear-like behaviors (K. S. Smith et al., 2012). In 
contrast, the study showed that BZs retained their anxiolytic-like effects in α1(H101R) 
mice as measured by the EPM test, suggesting that the α1-subtype is not essential for BZ-
induced anxiolysis (K. S. Smith et al., 2012). The fact that systemic injection of zolpidem 
produced debatable anxiolytic-like effects that were sensitive to experimental conditions 
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such as illumination of the maze (Savic et al., 2004) suggested that the role α1-subtype 
GABAARs play in mediating anxiolysis was influenced by complex variables.   
 
 In contrast to its role in fear and anxiety-like behaviors, the role the α1-subtype 
plays in sedation, aggression, amnesia and in addiction to BZs is better understood. The 
sedative effects of diazepam were abolished in the α1(H101R) mice, suggesting the 
involvement of α1-subtype GABAARs in sedation (McKernan et al., 2000). Similarly, the 
aggression-promoting effects of midazolam were abolished in α1(H101R) mice in a 
social interaction paradigm, suggesting the involvement of α1-subtype GABAARs in BZ-
induced escalation of aggression (Newman et al., 2015). Further, it is reported that 
systemic administration of β-CCT, a α1-subtype selective antagonist, reduced alcohol-
induced aggressive behaviors. However, interestingly, systemic administration of 
zolpidem did not increase ethanol-induced aggression, which could be attributed to the 
sedative effects of zolpidem (de Almeida, Rowlett, Cook, Yin, & Miczek, 2004). The 
amnesic effects of diazepam, as assessed by a passive-avoidance paradigm, was also 
abolished in α1(H101R) mice, suggesting the involvement of α1-subytpe GABAARs in 
memory processing (Rudolph et al., 1999). Similarly, amnesic / motor-impairing effects 
were also observed following systemic administration of zolpidem (Cope et al., 2004; 
Zanin et al., 2013), further reviewed in (Fitzgerald et al., 2014). Other studies have 
implicated α1-subtype GABAARs in drug abuse and addiction (Rowlett & Lelas, 2007; 
Tan, Rudolph, & Luscher, 2011), as well as in anxiety induced by acute BZ-withdraw 
(Divljakovic et al., 2013). 
 
 Several studies have begun to elucidate the specific roles played by α1-subtype 
GABAARs in different brain areas. Deletion of α1-subtype GABAARs within the 
amygdala reportedly disrupted the anticonvulsant and sedative effects of BZ. However, 
the anxiolytic-like effects of BZ, as measured by the EPM, were unaffected, suggesting 
that the α1-subtype is not essential for amygdala-mediated anxiety-like behaviors (Heldt 
& Ressler, 2010). Conversely, microinjection of zolpidem to the BNST resulted in 
anxiolytic-like effects, as measured by the open field test (Gafford et al., 2012). These 
results suggest that the role played by α1-subtype GABAARs in fear and anxiety-like 
behaviors is brain region specific.  
 
 Together, current evidence suggests that the α1-subtype GABAARs are involved 
in sedative, amnesic, and addictive effects of BZs (Rudolph & Knoflach, 2011). On the 
basis of currently published studies, the relative importance of the α1-subtype GABAARs 
in mediating BZ-induced anxiolytic-like behaviors is ambiguous, however its role may 
depend upon the specific brain regions, the behavioral test conditions, and the particular 
responses used to assess anxiety-like behaviors.  
 
 
The α2-subtype GABAARs 
 
 The role that α2-subtype GABAARs play in BZ-induced reductions of fear and 
anxiety-like behaviors is well documented. The inhibitory effects of diazepam and CDP 
on anxiety-like behavior, as measured by the EPM, and fear-like behavior, as measured 
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by fear potentiated startle test, were reduced in α2(H101R) mice (Low et al., 2000; K. S. 
Smith et al., 2012). Genomic deletion of the α2-subunit also abolished the anxiolytic-like 
effects of diazepam (Dixon, Rosahl, & Stephens, 2008). In contrast, a study showed that 
the sedative effects of diazepam were weakened in α1(H101R) mice that possess BZ-
sensitive α2-subtype GABAARs when compared to induced sedation in WT mice 
(McKernan et al., 2000). This evidence suggests that α2-subtypes are not overtly 
involved in BZ-induced sedation.  
 
 The above findings showing that lack of involvement of α2-subtype in sedation 
support the theory that α2-subtype selective PAMs might be good candidates for use as 
day-time anxiolytic drugs, as the sedative effects of classic BZs are problematic for their 
day-time use (Rudolph & Knoflach, 2011). In recent years, two compounds that have 
preferential efficacy at both α2- and α3-subtype GABAARs, TPA023 and TPA023B, have 
been developed and tested in animal experiments as well as clinical trials. In both animals 
and humans, these compounds reduce anxiety without major sedative effects even at high 
dose, however, issues with toxicity complicated the continuation of a clinical trial (Atack, 
2010b; Atack, Wafford, et al., 2006).  
 
 The putative α2-subtype selective agonist TCS-1105 (also known as “compound 
1c”) reportedly exerted anxiolytic-like effects as measured by the light-dark box test 
(Taliani et al., 2009). However, since the selectivity of this compound was tested in 
α1β2γ2, α2β2γ2, and α5β3γ2 recombinant GABAARs, but not α3-containing GABAARs, 
the selectivity of this compound in α2-subtype versus α3-subtype is unclear at present. 
Currently, a reliable α2-subtype selective compound is sought-after by the field.  
 
 The α2-subtype GABAARs are also implicated in regulating depression-like 
behaviors (Engin, Liu, & Rudolph, 2012; Vollenweider, Smith, Keist, & Rudolph, 2011) 
and the myorelaxation effects of BZs in mice (Crestani et al., 2001). Further, recent 
pharmacological studies as well as human genetics revealed that α2-subtype GABAARs 
are also involved in reward-related behaviors and addiction (Dixon et al., 2010; Engin et 
al., 2014). This evidence might argue against the use of α2-selective PAM for anxiety 
management as habit-forming might be a possible side-effect.  
 
 To sum up, current evidence suggests that α2-subtype GABAARs are implicated 
in anxiety-like, depression-like and schizophrenia-like behaviors and are a promising 
target for the development of novel therapeutics (Engin et al., 2012). 
 
 
The α3-subtype GABAARs 
 
 Currently, the role that α3-subtype GABAARs play in fear and anxiety is still 
debatable. On one hand, in an experiment using point mutant mice, it is reported that 
systemic injection of diazepam retained its effects in inducing anxiolysis as well as fear 
reduction in α3(H126R) mice carrying BZ-insensitive α3-subtype GABAARs (K. S. 
Smith et al., 2012). Genomic knockout of the α3-subunit did not affect baseline anxiety 
behavior or diazepam-induced anxiolysis (Yee et al., 2005). These findings suggest that 
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the α3-subtype GABAARs are not essential for mediating anxiety and BZ-induced 
anxiolysis. On the other hand, studies using the α3-subtype selective PAM TP003 
showed that systemic injections produced anxiolytic-like effects, as measured by the 
EPM and stress-induced hyperthermia in rodents as well as by a conflict test paradigm in 
primates (Dias et al., 2005; Fischer et al., 2011). In a conditioned emotional response 
paradigm, the α2-, α3- and α5-subtype selective compound, L-838417 retained its 
anxiolytic-like effects in α2(H101R) mice, suggesting that α3- and/or α5-subtype 
GABAARs mediate L-838417-induced anxiolysis independent of α2-subtype GABAARs 
(Morris, Dawson, Reynolds, Atack, & Stephens, 2006). In another study, the systemic 
injections of the α3-subtype selective BZ-site inverse agonist named Alpha3IA produced 
an anxiogenic-like profile as measured by the EPM in rodents (Atack et al., 2005). 
Together, these studies suggest that selective modulation of α3-subtype GABAARs by 
BZ-site ligands is sufficient to alter anxiety-like behaviors. Further, it is reported that 
blockade of 5-HT1A receptors reversed the anxiolytic-like effects elicited by TP003 in a 
stress-induced hyperthermia paradigm. This finding suggests that α3-subtype GABAARs 
are involved in the interaction between GABAergic and serotonergic transmission 
(Vinkers, van Oorschot, Korte, Olivier, & Groenink, 2010). Together, current findings 
suggest that α3-subtype GABAARs play a sufficient, but not necessary role in mediating 
anxiety-like behaviors and BZ-induced anxiolysis. 
 
 Similar to α2-subtypes, it is generally accepted that α3-subtype GABAARs are not 
overtly involved in BZ-induced sedation as diazepam failed to elicit sedative effects in 
α1(H101R) mice with intact α3-subtype GABAARs at doses that would induce sedation 
in WT mice (McKernan et al., 2000). It is also reported that α3-subtype GABAARs 
appeared to be non-essential for mediating the effects of BZ on sleep EEG (Kopp, 
Rudolph, Keist, & Tobler, 2003). Lack of α3-subtype GABAARs resulted in 
hyperdopaminergic and schizophrenia-like behavioral phenotypes hallmarked by 
sensorimotor gating deficits which could be reversed by treatment of antipsychotic drug 
haloperidol, suggesting that α3-subtype GABAARs’ involvement in schizophrenia (Yee et 
al., 2005). Similar to α2-subtype, the α3-subtype GABAARs are also involved in 
myorelaxation effects of BZs in rodents as well as in primates (Crestani et al., 2001; 
Fischer et al., 2011). Currently, little is known about whether the α3-subtype GABAARs 
are also involved in the addictive property of BZs or not.  
 
 To sum up, current evidence suggests that α3-subtype GABAARs play a role in 
mediating anxiolytic-like and myorelaxative, but not sedative effects of BZs. The α3-
subtype GABAARs are also implicated in schizophrenia-like behaviors in rodents.  
 
 
The α5-subtype GABAARs 
 
 The α5-subtype GABAARs differed from α1-, α2-, and α3-subtypes in that their 
expression, on the protein level, is enriched the olfactory bulb, hippocampus and spinal 
trigeminal nucleus, and their expression elsewhere is comparatively low (Fritschy & 
Mohler, 1995; Mathiasen et al., 2007; Pirker et al., 2000). Further, their subcellular 
expression patterns are mainly extrasynaptic and, thus they are thought to mediate tonic 
 16 
GABAergic inhibition (Crestani et al., 2002; Farrant & Nusser, 2005; Fritschy, Johnson, 
Mohler, & Rudolph, 1998; Groen et al., 2014). Due to the recognized involvement of the 
hippocampus in learning and memory processes, the prominent enrichment of α5-subtype 
GABAARs in the hippocampus was postulated to play specific roles in mediating learning 
and memory. The α5-subunit knockout mice performed better in a spatial learning task 
(Collinson et al., 2002), and inverse agonism of the α5-subtype by a compound named L-
655,708 resulted in cognitive improvement both under normal physiological conditions, 
and after general isoflurane-induced anesthesia where short-term memory was markedly 
impaired (Atack, Bayley, et al., 2006; Zurek, Bridgwater, & Orser, 2012). 
 
 Currently, the evidence for the involvement of α5-subtype GABAARs in anxiety 
is limited and contradictory. Mice with genetic deletion of the α5-subunit (α5-subunit 
KO) performed similarly to WT mice on the EPM test and in response to BZ (Collinson 
et al., 2002). Administration of a α5-subtype selective inverse agonist, α5IA, also did not 
significantly alter anxiety-like behaviors in rodents (Dawson et al., 2006). However, a 
study indicated that administration of another α5-subtype selective inverse agonist, L-
655,708, resulted in anxiogenic-like effects in the EPM paradigm (Navarro, Burón, & 
Martı́n-López, 2002), although questions were raised as to whether these effects were 
indeed mediated exclusively by the α5-subtype GABAARs (Atack, Bayley, et al., 2006). 
Together, currently the majority evidence suggests that the α5-subtype GABAARs appear 
unnecessary for mediating anxiety-like behaviors.  
 
 
The α4- and α6-subtype GABAARs 
 
 The α4- and α6-subtype GABAARs differ from the abovementioned receptor 
subtypes, in that they are insensitive to BZs due to the lack of (i) a crucial histidine 
residue required for the formation of functional BZ-site, and (ii) their preferential 
association with the δ-subunit (Caruncho & Costa, 1994; Sur et al., 1999; Wafford et al., 
1996; Wieland, Lüddens, & Seeburg, 1992). They are known to mediate extrasynaptic 
tonic GABAergic inhibition (Belelli et al., 2009; Brickley & Mody, 2012; Farrant & 
Nusser, 2005; Hamann, Rossi, & Attwell, 2002).  
 
 One feature of α4-subtype GABAARs is their sensitivity towards neurosteroid and 
hormonal modulation. This sensitivity was postulated to be involved in mediating many 
sex-differences in anxiety states, such as premenstrual, post-partum as well as peri-
puberty anxiety (Gulinello, Gong, Li, & Smith, 2001; Gulinello, Orman, & Smith, 2003; 
Shen et al., 2007; S. S. Smith et al., 1998). The α4-subtype GABAARs are also regulated 
by stress hormones and steroids, such as corticotrophin releasing hormone and 3α,5α[β]-
THP, and are thought to be a key player in mediating stress and anxiety responses in a 
sex dependent manner (Mody & Maguire, 2011; Shen, Mohammad, Ramroop, & Smith, 
2013; S. S. Smith, 2013; S. S. Smith, Shen, Gong, & Zhou, 2007).  
 
 Limited evidence indicates that α6-subtype GABAARs are involved in regulating 
fear and anxiety, amongst other behaviors and physiological functions. One report 
showed that midazolam-induced anxiolysis is attenuated in human subjects carrying the 
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Pro385Ser mutation in the α6-subunit (Hoffman, Balyasnikova, Mahay, Danilov, & 
Baughman, 2002). Some evidence also suggested that genetic variation within the α6-
subunits is associated with epilepsy in human (Hernandez, Gurba, Hu, & Macdonald, 
2011; Hirose, 2014). Also, a reduction of α6-subunit protein expression was reported in 
the superior frontal cortex of autistic subjects (Fatemi et al., 2014). Further, α6-subtype 
GABAARs are also implicated in alcohol dependency (Loh & Ball, 2000).  
 
 In summary, the α4- and α6-subtype GABAARs exhibit distinct physiological, 
pharmacological, and functional profiles that set them apart from the other BZ-sensitive 
GABAAR subtypes. In this study, we will mostly focus on the GABAAR subtypes that are 
both BZ-sensitive and abundantly expressed in the amygdala, i.e., the α1-, α2-, α3-
subtypes.  
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CHAPTER 3.    METHODOLOGY 
 
 
Mouse Strains 
 
 C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine) were used in this study 
as WT controls to test the anxiolytic profile of various selective and non-selective 
GABAAR PAMs in both systemic and intra-BLA microinjection experiments. This strain 
of mice are widely used in behavioral studies and their characteristic patterns of anxiety 
and fear-like behaviors are well understood. For example, C57BL/6J showed lower 
baseline anxiety level and higher sensitivity to BZ when compared to BALB/c mice 
(Lepicard, Joubert, Hagneau, Perez-Diaz, & Chapouthier, 2000), and they also showed 
slower fear extinction when compared to DBA/2J mice (Waddell, Dunnett, & Falls, 
2004).  
 
 In experiments that examined the functional silencing of selective GABAAR-
subtypes towards the modulatory effects of BZs, GABAAR point mutant mice, 
generously gifted by Dr. Uwe Rudolph from McLean Hospital, were used. These strains 
of mice were created in the last decade and have become of great value in the 
investigation of the selective function of different subunits (Rudolph & Mohler, 2004). 
Three lines of point mutant mice were used in our experiment: α1(H101R), α2(H101R), 
and α3(H126R). As previously described (Low et al., 2000; Rudolph et al., 1999; K. S. 
Smith et al., 2012), these mice have a mutated residue (histidine to arginine) in the BZ 
binding site of a particular α-subunit, rendering the receptor insensitive to the modulatory 
effects of BZs. These mutant mice were maintained on C57BL/6J genetic background 
and bred as homozygotes. 
 
 All animals were housed in micro-isolation cages with ad libitum access to food 
and water, 12h light-dark cycle and controlled temperature / humidity. All animals used 
in this study were adult mice (between 2-6 months of age). For most experiments, male 
subjects were used, except for the systemic CDP injection experiment, where mice of 
both sexes were used. All testing procedures were conducted in the light-phase of the day 
and were approved by the Animal Care and Use Committee of the University of 
Tennessee Health Science Center.   
 
 
Surgery Procedures  
 
 Stereotaxic surgeries were performed using procedures previously described in 
detail (Heldt & Ressler, 2006). Adult mice were anesthetized with an intraperitoneal (i.p.) 
injection of a cocktail of ketamine (80mg/kg) and xylazine (10mg/kg). Upon 
confirmation of anesthesia, their heads were shaved, swabbed with betadine, and 
mounted in a stereotaxic surgical frame (David Kopf Instruments, Tujunga, CA) with 
metal ear bars inserted and secured. Ophthalmic ointment was applied to prevent the eyes 
from drying out. An incision along the midline of the skull was made, and the 
surrounding skin was retracted to expose the surgical site. Two anchoring screws were 
then implanted. Holes were drilled in the skull over the intended cannula implantation 
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sites and bilateral 26 gauge guide cannulae (PlasticOne, Roanoke, VA) were planted 
stereotaxically at the following coordinates in reference to Bregma : AP:-1.5, ML: ±3.3 
or ±3.4, DV: -5.0 or -5.1 according to a reference stereotaxic atlas (Paxinos & Franklin, 
2001). The cannula fixture was secured with dental cement and the surgical incision was 
closed with adhesives. After surgery, animals were placed on a heating pad for recovery 
and a dose of post-operation analgesics (Buprenorphine 0.1 mg/kg or Carprofen 5.0 
mg/kg) was administered. Animals were then allowed to fully recover from surgery for at 
least 4 days, during this period they were closely monitored for signs of pain and distress. 
They were also handled with gloved hand daily to allow acclimation to the gentle 
restraint required for the microinjection procedure, and to minimize the stress induced by 
the injection procedure preceding the behavioral test.  
 
 
Pharmacological Agents 
 
 Many BZ-site ligands are known to exert positive allosteric modulatory effects on 
GABAARs. Non-selective classic BZs (e.g., CDP) are promiscuous to α1-, α2-, α3-, and 
α5-subtype GABAARs, on the other hand, subtype selective BZ-site ligands are defined 
as having either preferential affinity (e.g. zolpidem) and/or preferential efficacy (e.g. L-
838417 and TP003) towards a particular subset of BZ-sensitive α-subtypes (Rudolph & 
Knoflach, 2011).  
 
 
Chlordiazepoxide 
 
 Chlordiazepoxide (CDP, Sigma Aldrich, St Louis, MO), a classic BZ and 
nonselective GABAARs PAM, was used to augment the α1-, α2-, α3-, and α5-subtype 
GABAARs in systemic and intra-BLA microinjection experiments. CDP absorbs well 
after i.p. injection and a 5mg/kg i.p. injection in rats results in 25% receptor occupancy in 
the brain (Dias et al., 2005). For CDP systemic injection experiments, we used 10mg/kg 
as the high dose. The dose was chosen based on a previous systemic injection study that 
used the same dose as the high dose for mice (K. S. Smith et al., 2012). For CDP 
microinjection experiments, we used 20µg/µL as the high dose working concentration 
and 0.3µL injection volume was delivered. This was based on a previous microinjection 
study that used the same concentration of CDP (20µg/µL) with 0.5µL injection volume as 
the high dose for rats (Stackman & Walsh, 1995).  
 
 
Zolpidem 
 
 Zolpidem (Toronto Research Chemicals, North York, ON, Canada), a selective 
BZ-site PAM of α1-subtype GABAARs with ~5-fold selectivity over other subtypes 
(Petroski et al., 2006), was used to selectively augment α1-subtype GABAARs in both 
systemic injection experiments and intra-BLA microinjection experiments. The binding 
affinity of zolpidem is drastically reduced in α1(H101R) mice (McKernan et al., 2000). 
Zolpidem absorbs well after i.p. injection. In mice, an i.p. dose of 1.8mg/kg results in 
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approximately 50% receptor occupancy in the brain (Hopkins, Brian Nofsinger, Allen, 
Koch, & Varney, 2009). Ranges of drug dosages used in this study were carefully chosen 
based on previously published studies. For the zolpidem systemic injection experiment, 
we used 2mg/kg as the high dose. The dose was chosen based on a previous systemic 
injection study that used 3mg/kg as the high dose for mice and reported sedative effects 
at this dose (Mathiasen, Mirza, & Rodgers, 2008). We also observed pronounced motor 
impairment even at 2mg/kg dose that rendered the mice unable to reliably perform in the 
EPM test, thus we used 2mg/kg as the high dose for our experiment. For the zolpidem 
microinjection experiment, we used 0.5µg/µL as the high dose working concentration 
and 0.3µL injection volume was delivered. This was based on a previous microinjection 
study that used 0.25µg/µL concentration and 0.5µL injection volume as the working dose 
for mice (Gafford et al., 2012). 
 
 
L-838417 
 
 L-838417 (Tocris, Bristol, UK) is a selective BZ-site PAM that binds to α1-, α2-, 
α3-, and α5-subtype GABAARs, but only exerts positive modulatory effects on the α2-, 
α3-, and α5-subtypes in recombinant receptors. The binding affinity of L-838417 is lower 
in α5-subtype when compared to α1-, α2-, α3-subtypes. Further, although no direct 
evidence is available about the binding affinity of L-838417 for α3(H126R) receptors, it 
is known that the binding affinity of L-838417 is drastically reduced in α1(H101R) 
receptors (McKernan et al., 2000). Since both the α1- and α3-subtypes share similar BZ-
site structure that requires the histidine residue, we deduce that the binding affinity of L-
838417 should also be lost in α3(H126R) receptors. L-838417 absorbs well after i.p. 
injection. In mice, a dose of 1mg/kg or 3mg/kg i.p. injection results in 30-40% receptor 
occupancy in the brain (Scott-Stevens, Atack, Sohal, & Worboys, 2005), although a more 
recent study reports that the OC50 is around 1.3mg/kg (Hopkins et al., 2009). For the L-
838417 systemic injection experiment, we used 2mg/kg as the high dose. This dose was 
chosen based on a previous systemic injection study that found anxiolytic-like effects at 
3mg/kg dose in a Vogel conflict test for mice and in a conditioned emotional response 
test for rat (Mathiasen et al., 2008; Mathiasen et al., 2007). In an initial experiment, we 
found robust anxiolytic-like effects at 2mg/kg and even with a 0.5mg/kg dose in WT 
mice. Thus, we used 2mg/kg as the high dose in our experiment. For the L-838417 
microinjection experiment, we used 0.5µg/µL as the high dose working concentration 
and 0.3µL injection volume was delivered. This was based on a previous microinjection 
study that used 0.4µg/µL concentration and 1µL injection volume as the working dose for 
rats (Mathiasen et al., 2007).  
 
 
TP003 
 
 TP003 (Tocris, Bristol, UK) is a α3-subtyp.e selective BZ-site PAM (Dias et al., 
2005; Marowsky, Rudolph, Fritschy, & Arand, 2012). In vitro, TP003 binds to α1-, α2-, 
α3-, and α5-subtype GABAARs with high affinity, but only exerts positive modulatory 
effects on the α3-subtype in recombinant GABAARs. The binding affinity of TP003 is 
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drastically reduced in α2(H101R) receptors (Dias et al., 2005). TP003 absorbs well after 
i.p. injection. In rat, a 0.3 mg/kg i.p. injection resulted in 75% receptor occupancy in the 
brain (Dias et al., 2005). For TP003 systemic injection experiment, we used 2mg/kg as 
the high dose. This dose was chosen based on a previous systemic injection study that 
found anxiolytic-like effects at 3mg/kg dose for mice (Dias et al., 2005). In an initial 
experiment, we found robust anxiolytic-like effects at 2mg/kg and even a 0.5mg/kg dose 
in WT mice, thus we used 2mg/kg as the high dose in our experiment. Presently, to the 
best of our knowledge, no studies have attempted microinjection of TP003 in the brain. 
For this reason, we chose to use a range of concentrations, which were comparable to that 
of zolpidem and L-838417 microinjections, for TP003 microinjection. This was based on 
our initial findings showing that TP003 had comparable dose response relationships to 
zolpidem and L-838417 at similar concentrations in systemic injection experiments as 
measured by the EPM.  
 
 
Vehicle  
 
 Due to the poor solubility of many drugs used in this study in aqueous solutions, 
several vehicles were used to accommodate the doses required for particular experiments. 
For systemic injection and intra-BLA microinjection of selective drugs, the compounds 
were dissolved in a vehicle consisting of 10% DMSO and 20% cyclodextrin in 0.85% 
saline. For systemic injection of CDP, the drug was dissolved in 0.85% saline. For intra-
BLA microinjection of CDP, most groups received drugs dissolved in a vehicle 
consisting of 10% DMSO in 0.85% saline, except for the α2(H101R) mice groups, where 
half of the mice (balanced numbers across treatment groups) received drugs dissolved in 
a vehicle consisting of 10% DMSO and 20% cyclodextrin in 0.85% saline during a 
transition period. 
 
 
Injection Procedures 
 
 For the systemic injection experiments, drug solutions were delivered via i.p. 
injection 30 min before the EPM test (described below). For microinjection experiments, 
0.3µL of drug solution was delivered gradually over the course of 30 seconds using a 
5µL Hamilton syringe connected to a 33 gauge microinjector (PlasticOne, Roanoke, VA) 
manually. The injector was left in the cannula for 1 min after each injection to reduce 
backflow of injected solution. After completing bilateral microinjection, the animal was 
returned to a holding cage for 5-8 min before being tested on the EPM.  
 
 
Elevated Plus Maze 
 
 The EPM is a widely used test apparatus for measuring anxiety-related behaviors 
in rodents (Pellow & File, 1986). The apparatus used in this study had transparent 
plexiglass for the walls and opaque plexiglass for the floor. The dimensions of the maze 
are illustrated in Figure 3-1. The maze was located in a dedicated behavioral testing  
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Figure 3-1. Illustration of the Dimension of EPM Apparatus Used in This Study. 
 
Schematic drawing of the dimensions of the elevated plus maze (EPM) apparatus. The 
closed arm walls were constructed using transparent plexiglass, and the floor of the maze 
was constructed using opaque material 
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room and was illuminated with dim ambient light from the ceiling. The experimenter was 
located behind a curtain and was invisible to the mice during the test. Video was recorded 
during the test (5 min duration) with an overhead camera and the movement of the 
subject was tracked by ANY-Maze software (Stoelting, Wood Dale, IL).  
 
 Rodents generally have a native aversion to the open and elevated spaces where 
they are exposed to the surrounding open environment, and thigmotaxis (in this case, the 
tendency to remain in close proximity to the walls of the closed arm) is typically 
observed (Filgueiras, Carvalho-Netto, & Estanislau, 2014). Anxiety-like behavior is 
traditionally measured by preference for the closed arm over the open arm. Classic 
anxiolytic drugs, such as BZs, reportedly reduce an animal’s aversion to the open arm, 
e.g. (K. S. Smith et al., 2012). On the other hand, traumatic events, such as exposure to 
immobilization stress, typically enhance the aversion to the open arm (Viswanatha, 
Shylaja, Sandeep Rao, Santhosh Kumar, & Jagadeesh, 2012). 
 
 We measured the commonly reported EPM parameters including the percentage 
of time in the open arm, the percentage of open arm entry, and the distance traveled 
during the test. We also recorded several parameters that are not often reported in the 
EPM tests. First, we observed a subtle difference in the animal’s behavior in the proximal 
open arm (where they could quickly flee and hide in the closed arm) as opposed to the 
distal open arm (where they were far away from their “safe zone” and were highly 
exposed to the surrounding open environment), we collected the time the animal spent in 
and the entry to the distal open arm as more sensitive measurements of anxiety-like 
behaviors. Second, as we consistently observed the animals’ risk-assessing behavior 
characterized by extending their head outside the edge of the open arm to investigate the 
surrounding environment, we counted the number of such investigatory behaviors (head 
dips) as an index of risk assessment by the subject. Of note, the parameter “head dips” 
was operationally defined here as the incidences where the animal extended its head over 
the edge of the open arm, rather than as downward movements of the head. Our pilot data 
showed a clear increase of this behavior in BZ-treated mice. Together, the EPM test gave 
us both the traditional measurements of anxiety in addition to some potentially more 
sensitive measurements of the animal’s subtle behaviors on the maze, and allowed us to 
reliably quantify the effects of drug treatment on anxiety-like behaviors.  
 
 To score the activities in the open or closed arm, the software tracked the animal’s 
entire body area to effectively reducing the spurious counts of entry/exit when the animal 
hesitantly moved its body around the boundary of the center zone. To count an entry, 
80% of the animals' body must enter an open or closed arm. To count an exit, the animal 
must fail to retain 70% of its body in an open or closed arm. For activities in the distal 
open arm, the software tracked the center of the animal’s body. For counting head dips, 
the software tracked the head of the animal. An example of the animal’s behavior on the 
EPM with or without BZ treatment is illustrated in Figure 3-2 as an occupancy plot heat-
map. 
 
 Based on an initial assessment, we found that many of the parameters collected 
during the EPM task were correlated with each other. For the clarity of the data  
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Figure 3-2. Illustration of the Effects of BZ on Animals Behavior on the EPM 
 
Typical occupancy plot heat-maps of animals’ behavior on the elevated plus maze (EPM) 
with or without benzodiazepine (BZ) treatment. BZ treatment increased the animals’ 
activity on the open arm (O.A.). 
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presentation we reported the following parameters as the main indicators of the animal’s 
behavior on the EPM: percentage of time in the open arm (% O.A. Time), percentage of 
open arm entry (% O.A. Entry), number of head dips (Head Dips), and overall distance 
travelled on the EPM (Distance). The first three measurements are indicators of the 
anxiety level and the investigatory behaviors of the subject. The fourth measurement is an 
indicator of the motor activity of the subject. Descriptive statistics of other dependent 
measures such as distal open arm (D.O.A) Time and number of D.O.A. Entry were 
presented in tables. 
 
 
Data Evaluation and Reduction  
 
 After behavioral testing, animals were euthanized and 1% Evan’s blue dye 
solution (0.3µL) was microinjected via the guide cannula. Brains were rapidly collected, 
frozen over dry ice, and coronally sectioned on a cryostat to verify cannula placement. A 
typical spread of dye is illustrated in Figure 3-3. The whole brain images were taken with 
a Olympus BX50 microscope (Olympus, Center Valley, PA), stitched together using the 
Stitching plugin, and background subtracted using Fiji (Preibisch, Saalfeld, & Tomancak, 
2009; Schindelin et al., 2012; Schneider, Rasband, & Eliceiri, 2012).  
 
 Subjects with misplaced cannula, as identified by the spread of the dye and the 
imprint left by the cannula, were subsequently excluded prior to data analysis (13 out of 
204 mice in the intra-BLA microinjection experiments). In most cases, excluded animals 
had off-target injection sites that showed significant dye diffusion or cannula tract imprint 
in the CeA, cortex, or ventricle.  
 
 The EPM is a locomotion-dependent task (Reynolds, McKernan, & Dawson, 
2001), and the accurate measurement of anxiety-like indexes, especially the % O.A. 
Entry, depends on adequate locomotion of the animal on the maze for reliable 
calculation. The average distance traveled during the 5 minutes test period across all 
subjects was 9.4 ± 0.2 meters (mean ± SEM). Subjects who traveled less than 2 meters 
during the 5 min test period, which occurred rarely (2%), were excluded from statistical 
analysis. In most cases, these animals traveled a short distance after placement in the 
EPM, and remained immobile for the remainder of the test session. An exception to this 
rule was allowed for the experiments with zolpidem, in which we also planned to 
examine the anticipated relationship between anxiety and sedation prior to the 
experiment. In addition, animals that fell off the maze during the test were excluded from 
the study. Finally, a few animals were excluded from analysis due to malfunction of the 
video tracking software. In total, 9 out of 204 mice in intra-BLA microinjection 
experiment and 6 out of 345 mice in systemic injection experiment were excluded 
because of either immobility, displacement from the maze, or tracking problems. 
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Figure 3-3. Illustration of Bilateral Dye Injection Showing the Injection Sites 
 
A typical dye injection result showing successful bilateral microinjections targeting the 
basolateral amygdala (BLA), while sparing the central nucleus (CeA).  
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Statistical Analysis 
 
 For all experiments, a one-way analysis of variance (one-way ANOVA) with % 
O.A. Time, % O.A. Entry, Head Dips, and Distance as dependent variables and dose of 
the drug as the independent variable were performed to assess the overall differences 
among groups. Dunnett's post hoc multiple comparison test (Dunnett, 1955, 1964) was 
used to compare drug injected groups against the vehicle injected group to assess the 
effects of drug treatment at a particular dose. For the systemic injection of CDP 
experiment, because both males and females were used, two-way analysis of variance 
(two-way ANOVA) with % O.A. Time, % O.A. Entry, Head Dips, and Distance as 
dependent variables and dose and sex as independent variables was performed to assess 
the overall effects of sex and drug treatment. One-way ANOVA and Dunnett’s post hoc 
test, as described above, were subsequently performed within each sex group. The α-
value of significance was set at 0.05 for both ANOVA and Dunnett’s test. In all of the 
figures, data were reported as means ± SEM. Asterisks represent significant differences 
between the vehicle injected control group and the drug injected experimental groups as 
assessed by post hoc Dunnett's comparisons, unless stated otherwise. *p < 0.05; **p < 
0.01; ***p < 0.001. 
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CHAPTER 4.    RESULTS 
 
 
Systemic Injection of Selective GABAAR PAMs 
 
 To assess the differential roles of each GABAAR subtype in mediating BZ-
induced anxiolysis on the systemic level, subtype selective GABAAR PAMs were acutely 
administered to both adult male C57BL/6J mice and several strains of point mutant mice 
via systemic (i.p.) injection. The effects of the drugs on anxiety-like behaviors and motor 
activities were assessed by the EPM test.  
 
 
Systemic Injection of Zolpidem in WT C57BL/6J Mice 
 
 To assess the role α1-subtype GABAARs play in mediating anxiolysis, WT 
C57BL/6J mice were given an i.p injection of the α1-subtype selective PAM, zolpidem, 
at one of the following doses: 0.25mg/kg, 0.5mg/kg, 1mg/kg, or 2mg/kg. Mice were 
tested on the EPM 30 min post-injection. The results are shown in Figure 4-1. One-way 
ANOVA with dose as the independent variable revealed significant effects of zolpidem 
on the dependent variables of % O.A. Entry, Head Dips, and Distance traveled on the 
EPM, Fs(4, 35) > 4.15, ps < 0.01. No significant effect of zolpidem was found on the % 
O.A. Time, F(4, 35) = 2.39, p = 0.07. Dunnett's comparisons revealed zolpidem exerted 
anxiolytic-like effects as measured by significantly increased % O.A. Entry at 0.5mg/kg 
and 1mg/kg doses (ps < 0.05). Zolpidem also exerted significant motor-inhibiting effects 
as measured by significantly reduced distance traveled on the EPM at 1mg/kg and 
2mg/kg doses (ps < 0.05). Further, zolpidem significantly reduced the Head Dips at 
2mg/kg dose (p < 0.05), which was likely an effect correlated with motor inhibition. A 
total of 40 mice were included in this experiment (Veh, n=12; 0.25mg/kg, n=8; 0.5mg/kg, 
n=7; 1mg/kg, n=7; and 2mg/kg, n=6).  
 
 
Systemic Injection of L-838417 in WT C57BL/6J Mice 
 
 To assess the that role α2-, α3-, (and α5-) subtype GABAARs play in mediating 
anxiolysis, WT C57BL/6J mice were given an i.p. injection of the α2-, α3-, (and α5-) 
subtype selective PAM, L-838417, at one of the following doses: 0.5mg/kg, or 2mg/kg. 
Mice were tested on the EPM 30 min post-injection. The results are shown in Figure 4-2. 
One-way ANOVA with dose as the independent variable revealed significant effects of 
L-838417 on the dependent variables of % O.A. Time, % O.A. Entry, Head Dips, and 
Distance traveled on the EPM, Fs(2, 24) > 11.81, ps < 0.001. Dunnett's comparisons 
revealed L-838417 exerted anxiolytic-like effects as measured by significantly increased 
% O.A. Time and % O.A. Entry at 0.5mg/kg and 2mg/kg doses (ps < 0.001). L-838417 
significantly increased the Head Dips at 0.5mg/kg and 2mg/kg doses (p < 0.001). Further, 
L-838417 exerted significant motor-stimulating effects as measured by significantly 
increased distance traveled on the EPM at 0.5mg/kg and 2mg/kg doses (ps < 0.01). A  
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Figure 4-1. Systemic Injection of Zolpidem in WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05; **p < 0.01; ***p < 0.001.  
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Figure 4-2. Systemic Injection of L-838417 in WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. **p < 
0.01; ***p < 0.001.  
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total of 27 mice were included in this experiment (Veh, n=12; 0.5mg/kg, n=7; and 
2mg/kg, n=8).  
 
 
Systemic Injection of L-838417 in α3(H126R) Mice 
 
 To assess the role α2- (and α5-) subtype GABAARs play in mediating anxiolysis, 
α3(H126R) mice were given an i.p. injection of L-838417 at one of the following doses: 
0.5mg/kg, 2mg/kg. Mice were tested on the EPM 30 min post-injection. The results are 
shown in Figure 4-3. One-way ANOVA with dose as the independent variable revealed 
no significant effect on the dependent variables of % O.A. Time, % O.A. Entry, Head 
Dips, or Distance traveled, Fs(2, 22) < 3.28, p > 0.05. No post hoc Dunnett’s test was 
performed. A total of 25 mice were included in this experiment (Veh, n=11; 0.5mg/kg, 
n=7; and 2mg/kg, n=7).  
 
 
Systemic Injection of TP003 in C57BL/6J Mice 
 
 To assess the role the α3-subtype GABAARs play in mediating anxiolysis, 
C57BL/6J mice were given an i.p. injection of the α3-subtype selective PAM, TP003, at 
one of the following doses: 0.5mg/kg, or 2mg/kg. Mice were tested on the EPM 30 min 
post-injection. The results are shown in Figure 4-4. One-way ANOVA with dose as 
independent variable revealed significant effects of TP003 on the dependent variables of 
% O.A. Time, % O.A. Entry, Head Dips, and Distance traveled on the EPM, Fs(2, 23) > 
5.54, ps < 0.05. Dunnett's comparisons revealed TP003 exerted anxiolytic-like effects as 
measured by significantly increased % O.A. Time and % O.A. Entry at 0.5mg/kg and 
2mg/kg doses (ps < 0.001). TP003 significantly increased the Head Dips at 0.5mg/kg and 
2mg/kg doses (ps < 0.05). TP003 also exerted motor-stimulating effects as measured by 
significantly increased distance traveled on the EPM at 0.5mg/kg dose (p < 0.01). A total 
of 26 mice were included in this experiment (Veh, n=12; 0.5mg/kg, n=7; and 2mg/kg, 
n=7).  
 
 
Systemic Injection of Zolpidem in α1(H101R) Mice 
 
 To assess the selectivity of zolpidem towards α1-subtype GABAARs, α1(H101R) 
mice were given an i.p. injection of zolpidem at one of the following doses: 1mg/kg, or 
2mg/kg. As demonstrated previously, the dose 1mg/kg elicited anxiolytic-like effects in 
C57BL/6J mice, while the dose 2mg/kg elicited motor-inhibiting effects. Mice were 
tested on the EPM 30 min post-injection. The results are shown in Figure 4-5. One-way 
ANOVA with dose as the independent variable revealed no significant effects of 
zolpidem on the dependent variables of % O.A. Time, % O.A. Entry, Head Dips, and 
Distance traveled on the EPM, Fs(2, 19) < 2.07, ps > 0.1. This indicated that the 
zolpidem lost its effects in α1(H101R) mice, and supported the hypothesis that the effects 
of zolpidem seen in WT mice were indeed mediated by the α1-subtype GABAARs. A  
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Figure 4-3. Systemic Injection of L-838417 in α3(H126R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM.  
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Figure 4-4. Systemic Injection of TP003 in WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05; **p < 0.01; ***p < 0.001.  
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Figure 4-5. Systemic Injection of Zolpidem in α1(H101R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM.  
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total of 22 mice were included in this experiment (Veh, n=7; 1mg/kg, n=8; and 2mg/kg, 
n=7). 
 
 
Systemic Injection of TP003 in α2(H101R) and α3(H126R) Mice 
 
 To assess the selectivity of TP003 towards α3-subtype GABAARs, α2(H101R) 
and α3(H126R) mice were given an i.p. injection of TP003 at 2mg/kg dosage. As 
demonstrated previously, this dose elicited prominent anxiolytic-like effects in WT 
C57BL/6J mice. Mice were tested on the EPM 30 min post-injection. The results are 
shown in Figure 4-6. Two-tailed t-test comparisons revealed significant effects of TP003 
treatment on the dependent variables of % O.A. Time, % O.A. Entry, Head Dips, and 
Distance traveled on the EPM in α2(H101R) mice, ps < 0.05. No significant effect of 
TP003 was found on % O.A. Time, % O.A. Entry, or Head Dips in α3(H126R) mice. 
However, a significant effect of TP003 on Distance traveled on the EPM was found (p < 
0.05). Taken together, these data suggested that TP003 lost its anxiolytic-like effects in 
α3(H126R) mice but retained its anxiolytic-like effects in α2(H101R), and indicated that 
the anxiolytic-like effects were indeed mediated by α3-subtype GABAARs. Asterisks 
represented significant difference between the vehicle injected control group and the drug 
injected experimental group within each strain as assessed by two-tailed t-tests. A total of 
35 mice were included in this experiment, [α2(H101R)-Veh, n=8; α2(H101R)-2mg/kg, 
n=8; α3(H126R)-Veh, n=11; and α3(H126R)-2mg/kg, n=8]. *p < 0.05; **p < 0.01; NS: 
non-significant.  
 
 
Systemic Injection of Selective GABAAR PAMs – Other Parameters 
 
 Besides the parameters reported in the figures, descriptive statistics were obtained 
for several other parameters, including the distance traveled on the open arm and closed 
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm 
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center 
Time) during the EPM experimentation, are summarized in Table 4-1.  
 
 
Systemic Injection of Non-Selective CDP in Point Mutant Mice 
 
 To assess the effects of the non-selective BZ drug, CDP, on anxiety-like 
behaviors, CDP was administered to both C57BL/6J mice and three strains of point 
mutant mice α1(H101R), α2(H101R), and α3(H126R), via systemic (i.p.) injection. The 
effects of the drug on anxiety-like behaviors and motor activities were assessed by the 
EPM test. For this experiment, both males and females were used and were analyzed 
separately.  
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Figure 4-6. Systemic Injection of TP003 in α2(H101R) and α3(H126R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represented significant difference between the vehicle 
injected control group and the drug injected experimental group within each strain as 
assessed by two-tailed t-test. *p < 0.05; **p < 0.01; NS: non-significant.  
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Table 4-1. Systemic Injection of Selective GABAAR PAMs – Descriptive 
Statistics of Other Parameters 
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Systemic Injection of CDP in WT C57BL/6J Mice 
 
 To assess the anxiolytic-like effects of CDP, C57BL/6J mice were given an i.p 
injection of CDP at one of the following doses: 5mg/kg, or10mg/kg. Mice were tested on 
the EPM 30 min post-injection. The results are shown in Figure 4-7 and Figure 4-8. 
Two-way ANOVA with dose and sex as independent variables returned significant main 
effects of dose on the dependent variables of % O.A. Time, % O.A. Entry, and Head Dip, 
Fs(2,43) > 14.14, ps < 0.001. No significant effect of dose was detected on the dependent 
variable of Distance, F(2,43) = 2.806, p = 0.072. No significant effect of sex or Sex × 
Dose interaction was detected, ps > 0.1. 
 
 For males, one-way ANOVA with dose as independent variable revealed 
significant effects of CDP on the dependent variables of % O.A. Time, % O.A. Entry, 
and Head Dips, Fs(2, 18) > 5.29, ps < 0.05. No significant effect of CDP was detected on 
Distance traveled on the EPM, F(2,18) = 1.01, p > 0.05. Dunnett's comparisons revealed 
CDP exerted anxiolytic-like effects as measured by significantly increased % O.A. Time 
at 10mg/kg dose (p < 0.001) and % O.A. Entry at 5mg/kg and 10mg/kg doses (ps < 0.05). 
CDP significantly increased the Head Dips at 10mg/kg dose (p < 0.01). A total of 21 
mice were included in this experiment (Veh, n=8; 5mg/kg, n=6; and 10mg/kg, n=7).  
 
 For females, one-way ANOVA with dose as independent variable revealed 
significant effects of CDP on the dependent variables of % O.A. Time, % O.A. Entry, 
Head Dips, and Distance traveled on the EPM, Fs(2, 25) > 4.52, ps < 0.05. Dunnett's 
comparisons revealed CDP exerted anxiolytic-like effects as measured by significantly 
increased % O.A. Time, % O.A. Entry and Head Dips at 10mg/kg dose (ps < 0.001). 
CDP also exerted motor-stimulating effects as measured by significantly increased 
distance traveled on the EPM at 10mg/kg dose (p < 0.05). A total of 28 mice were 
included in this experiment (Veh, n=9; 5mg/kg, n=6; and 10mg/kg, n=13).  
 
 
Systemic Injection of CDP in α1(H101R) Mice 
 
 To assess the anxiolytic-like effects of CDP in mice expressing the BZ-insensitive 
α1-subtype GABAARs, α1(H101R) mice were given an i.p. injection of CDP at one of the 
following doses: 5mg/kg, or 10mg/kg. Mice were tested on the EPM 30 min post-
injection. The results are shown in Figure 4-9 and Figure 4-10. Two-way ANOVA with 
dose and sex as independent variables returned significant main effects of dose on the 
dependent variables of % O.A. Time, % O.A. Entry, Head Dip, as well as Distance, 
Fs(2,41) > 11.29, ps < 0.001. A significant main effect of sex on the dependent 
variable % O.A. Time was also detected, F(1,41) = 8.00, p < 0.01. No significant Sex × 
Dose interaction was detected.  
 
 For males, one-way ANOVA with dose as independent variable revealed 
significant effects of CDP on the dependent variables of % O.A. Entry, Head Dips, and 
Distance traveled on the EPM, Fs(2, 20) > 7.36, ps < 0.01. No significant effect of CDP 
was detected on the % O.A. Time, F(2,20) = 3.47, p = 0.0507. Dunnett's comparisons   
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Figure 4-7. Systemic Injection of CDP in Male WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
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Figure 4-8. Systemic Injection of CDP in Female WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05; ***p < 0.001.  
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Figure 4-9. Systemic Injection of CDP in Male α1(H101R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05; **p < 0.01; ***p < 0.001.  
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Figure 4-10. Systemic Injection of CDP in Female α1(H101R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05; **p < 0.01; ***p < 0.001.  
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revealed CDP exerted anxiolytic-like effects as measured by significantly increased % 
O.A. Entry at 10mg/kg dose (p < 0.01). CDP also significantly increased the Head Dips 
at 5mg/kg and 10mg/kg dose (ps < 0.05). A significant effect of CDP on motor activities 
was detected at the 5mg/kg and 10mg/kg doses (ps < 0.05). A total of 23 mice were 
included in this experiment (Veh, n=8; 5mg/kg, n=8; and 10mg/kg, n=7).  
 
 For females, one-way ANOVA with dose as independent variable revealed 
significant effects of CDP on the dependent variables of % O.A. Time, % O.A. Entry, 
and Head Dips, Fs(2, 21) > 6.15, ps < 0.01. No significant effect of CDP was detected on 
the Distance traveled on the EPM, F(2,21) = 2.82, p > 0.05. Dunnett's comparisons 
revealed CDP exerted anxiolytic-like effects as measured by significantly increased % 
O.A. Time and % O.A. Entry at 5mg/kg and 10mg/kg doses (ps < 0.01). CDP also 
significantly increased Head Dips at both 5mg/kg and 10mg/kg doses (ps < 0.05). A total 
of 24 mice were included in this experiment (Veh, n=8; 5mg/kg, n=8; and10mg/kg, n=8).  
 
 
Systemic Injection of CDP in α2(H101R) Mice 
 
 To assess the anxiolytic-like effects of CDP in mice with BZ-insensitive α2-
subtype GABAARs, α2(H101R) mice were given an i.p. injection of CDP at one of the 
following doses: 5mg/kg, or 10mg/kg. Mice were tested on the EPM 30 min post-
injection. The results are shown in Figure 4-11 and Figure 4-12. Two-way ANOVA 
with dose and sex as independent variables returned significant main effects of dose on 
the dependent variables of % O.A. Time, % O.A. Entry, and Distance, Fs(2,48) > 3.26, ps 
< 0.05. Significant main effects of sex on the dependent variables of % O.A. Entry and 
Head Dips were also detected, Fs(1,48) > 5.04, p < 0.05. A significant Sex × Dose 
interaction was detected on the dependent variable of Distance, F(2,48) = 6.11, p < 0.01. 
 
 For males, one-way ANOVA with dose as independent variable revealed 
significant effect of CDP on the dependent variable of Distance traveled, F(2,26) = 3.69, 
p < 0.05. No significant effect was found on the dependent variables of % O.A. Time, % 
O.A. Entry, and Head Dips, Fs(2, 26) < 2.32, ps > 0.1. Dunnett’s comparison revealed a 
significant difference in Distance traveled at 5mg/kg dose when compared to the Vehicle 
group (p < 0.05). A total of 29 mice were included in this experiment (Veh, n=11; 
5mg/kg, n=10; and 10mg/kg, n=8).  
 
 For females, one-way ANOVA with dose as independent variable revealed no 
significant effect of CDP on the dependent variables of % O.A. Time, % O.A. Entry and 
Head Dips, Fs(2, 22) < 3.11, ps > 0.05. A significant effect of CDP on Distance traveled 
on the EPM was found, F(2, 22) = 4.81, p < 0.05. However, post hoc Dunnett's 
comparison returned no significant difference of the drug injected groups from the 
vehicle injected group. A total of 25 mice were included in this experiment (Veh, n=10; 
5mg/kg, n=8; and 10mg/kg, n=7).  
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Figure 4-11. Systemic Injection of CDP in Male α2(H101R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05.  
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Figure 4-12. Systemic Injection of CDP in Female α2(H101R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM.  
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Systemic Injection of CDP in α3(H126R) Mice 
 
 To assess the anxiolytic-like effects of CDP in mice with BZ-insensitive α3-
subtype GABAARs, α3(H126R) mice were given an i.p. injection of CDP at one of the 
following doses: 5mg/kg, or 10mg/kg. Mice were tested on the EPM 30 min post-
injection. The results are shown in Figure 4-13 and Figure 4-14. Two-way ANOVA 
with dose and sex as independent variables returned significant main effects of dose on 
the dependent variables of % O.A. Time and % O.A. Entry, Fs(2,43) > 4.60, ps < 0.05. 
No significant effect of sex or Sex × Dose interaction was detected, ps > 0.05. 
 
 For males, one-way ANOVA with dose as independent variable revealed no 
significant effect of CDP on the dependent variables of % O.A. Time, % O.A. Entry, 
Head Dips, and Distance, Fs(2, 19) < 3.35, ps > 0.05. A total of 22 mice were included in 
this experiment (Veh, n=8; 5mg/kg, n=6; and 10mg/kg, n=8). 
 
 For females, one-way ANOVA with dose as independent variable revealed 
significant effects of CDP on the dependent variables of % O.A. Time, and % O.A. 
Entry, Fs(2, 24) > 4.51, ps < 0.05. No significant effect was detected on the Head Dips 
and Distance traveled on the EPM, Fs(2, 24) < 2.04, ps > 0.01. Dunnett's comparisons 
revealed CDP exerted anxiolytic-like effects as measured by significantly increased % 
O.A. Time and % O.A. Entry at 10mg/kg dose (ps < 0.05). A total of 27 mice were 
included in this experiment (Veh, n=7; 5mg/kg, n=8; and 10mg/kg, n=12).  
 
 
Systemic Injection of Non-Selective CDP – Other Parameters 
 
 Besides the parameters reported in the figures, descriptive statistics were obtained 
for several other parameters, including the distance traveled on the open arm and closed 
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm 
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center 
Time) during the EPM experimentation, are summarized in Table 4-2.  
 
 
Intra-BLA Microinjection of Selective GABAAR PAMs 
 
 To assess the differential role that GABAAR subtypes within the BLA play in 
mediating BZ-induced anxiolysis, subtype selective GABAAR PAMs were administered 
to both adult male C57BL/6J mice and α3(H126R) mice via intra-BLA microinjection. 
The effects of the drugs on anxiety-like behaviors and motor activities were assessed by 
the EPM.  
 
 
Intra-BLA Microinjection of Zolpidem in WT C57BL/6J Mice 
 
 To assess the role α1-subtype GABAARs play in mediating anxiolysis within the 
BLA, C57BL/6J mice were given bilateral intra-BLA microinjections of zolpidem at one   
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Figure 4-13. Systemic Injection of CDP in Male α3(H126R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM.  
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Figure 4-14. Systemic Injection of CDP in Female α3(H126R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05; **p < 0.01. 
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Table 4-2. Systemic Injection of Non-Selective CDP – Descriptive Statistics of 
Other Parameters 
 
 
 
 
  
 50 
of the following doses: 0.1µg/µL, 0.25µg/µL, or 0.5µg/µL in 0.3µL volume. Mice were 
tested on the EPM 5-8 min post-injection. The results are shown in Figure 4-15. One-
way ANOVA with dose as independent variable revealed significant effects of zolpidem 
microinjection on the dependent variables of % O.A. Time, and % O.A. Entry, Fs(3, 39) 
> 3.43, ps < 0.05. No significant effect on Head Dips and Distance traveled was detected, 
Fs(3, 39) < 2.07, ps > 0.1. Dunnett's comparisons revealed zolpidem exerted anxiolytic-
like effects as measured by significantly increased % O.A. Time at 0.1µg/µL dose (p < 
0.05). However, post hoc Dunnett’s test revealed no significant difference in the % O.A. 
Entry between the drug injected groups and the vehicle injected group. A total of 43 mice 
were included in this experiment (Veh, n=14; 0.1µg/µL, n=10; 0.25µg/µL, n=10; and 
0.5µg/µL, n=9).  
 
 
Intra-BLA Microinjection of L-838417 in α3(H126R) Mice 
 
 To assess the role the α2- (and α5-) subtype GABAARs play in mediating 
anxiolysis within the BLA, α3(H126R) mice were given bilateral intra-BLA 
microinjection of L-838417 at one of the following doses: 0.25µg/µL, or 0.5µg/µL in 
0.3µL volume. Mice were tested on the EPM 5-8 min post-injection. The results are 
shown in Figure 4-16. One-way ANOVA with dose as the independent variable revealed 
a significant effect of L-838417 microinjection in α3(H126R) mice on the dependent 
variables of Head Dips, F(2, 21) = 3.95, p < 0.05. No significant effect was detected on 
% O.A. Time, % O.A. Entry or Distance traveled, Fs(2, 21) < 2.96, p > 0.05. Dunnett's 
comparisons revealed L-838417 exerted anxiolytic-like effects as measured by 
significantly increased Head Dips at 0.5µg/µL dose (p < 0.05). A total of 24 mice were 
included in this experiment (Veh, n=10; 0.25µg/µL, n=7; and 0.5µg/µL, n=7).  
 
 
Intra-BLA Microinjection of TP003 in WT C57BL/6J Mice 
 
 To assess the role the α3-subtype GABAARs play in mediating anxiolysis within 
the BLA, WT C57BL/6J mice were given bilateral intra-BLA microinjections of TP003 
at one of the following dose: 0.1µg/µL, 0.25µg/µL, or 0.5µg/µL in 0.3µL volume. Mice 
were tested on the EPM 5-8 min post-injection. The results are shown in Figure 4-17. 
One-way ANOVA with dose as independent variable revealed significant effect of TP003 
microinjection in WT mice on the dependent variable of % O.A. Time, F(3, 37) = 5.11, p 
< 0.05. No significant effect on % O.A. Entry, Head Dips, or Distance traveled was 
detected, Fs(3, 37) < 2.34, p > 0.05. Dunnett's comparisons revealed TP003 exerted 
anxiolytic-like effects as measured by significantly increased % O.A. Time at 0.25µg/µL 
and 0.5µg/µL dose (ps < 0.01). A total of 41 mice were included in this experiment (Veh, 
n=14; 0.1µg/µL, n=9; 0.25µg/µL, n=8; and 0.5µg/µL, n=10).  
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Figure 4-15.  Intra-BLA Microinjection of Zolpidem in WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. **p < 
0.01.  
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Figure 4-16. Intra-BLA Microinjection of L-838417 in α3(H126R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05. 
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Figure 4-17.  Intra-BLA Microinjection of TP003 in WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. **p < 
0.01.  
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Intra-BLA Microinjection of Subtype Selective GABAAR PAMs – Other 
Parameters 
 
 Besides the parameters reported in the figures, descriptive statistics were obtained 
for several other parameters, including the distance traveled on the open arm and closed 
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm 
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center 
Time) during the EPM experimentation, are summarized in Table 4-3.  
 
Intra-BLA Microinjection of Non-Selective CDP in Point Mutant Mice 
 
 To assess the effects of a non-selective BZ drug, CDP, on anxiety-like behaviors 
within the BLA, CDP was administered to both C57BL/6J mice and three strains of point 
mutant mice, α1(H101R), α2(H101R), and α3(H126R), via intra-BLA microinjection. 
The effects of the drugs on anxiety-like behaviors and motor activities were assessed by 
the EPM. 
 
 
Intra-BLA Microinjection of CDP in WT C57BL/6J Mice  
 
 To assess the anxiolytic-like effects of CDP within the BLA, WT C57BL/6J mice 
were given bilateral intra-BLA microinjections of CDP at one of the following doses: 
10µg/µL, or 20 µg/µL in 0.3uL volume. Mice were tested on the EPM 5-8 min post-
injection. The results are shown in Figure 4-18. One-way ANOVA with dose as 
independent variable revealed no significant effect of CDP microinjection on the 
dependent variables of % O.A. Time, % O.A. Entry, Head Dips, or Distance traveled, 
Fs(2, 21) < 1.34, p > 0.1. A total of 24 mice were included in this experiment (Veh, n=9; 
10µg/µL, n=6; and 20µg/µL, n=9). 
 
 
Intra-BLA Microinjection of CDP in α1(H101R) Mice  
 
 To assess the anxiolytic-like effects of CDP within the BLA in mice expressing 
the BZ-insensitive α1-subtype, α1(H101R) mice were given bilateral intra-BLA 
microinjections of CDP at one of the following doses: 10µg/µL, or 20 µg/µL in 0.3uL 
volume. Mice were tested on the EPM 5-8 min post-injection. The results are shown in 
Figure 4-19. One-way ANOVA with dose as independent variable revealed no 
significant effect of CDP microinjection on the dependent variables of % O.A. Time, % 
O.A. Entry, Head Dips, or Distance traveled, Fs(2, 19) < 0.74, p > 0.1. A total of 22 mice 
were included in this experiment (Veh, n=8; 10µg/µL, n=7; 20µg/µL, n=7). 
 
 
Intra-BLA Microinjection of CDP in α2(H101R) Mice  
 
 To assess the anxiolytic-like effects of CDP within the BLA in mice expressing 
the BZ-insensitive α2-subtype, α2(H101R) mice were given bilateral intra-BLA   
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Table 4-3. Intra-BLA Microinjection of Subtype Selective GABAAR PAMs – 
Descriptive Statistics of Other Parameters 
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Figure 4-18. Intra-BLA Microinjection of CDP in WT C57BL/6J Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM.  
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Figure 4-19. Intra-BLA Microinjection of CDP in α1(H101R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM.  
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microinjections of CDP at one of the following doses: 10µg/µL, or 20 µg/µL in 0.3uL 
volume. Mice were tested on the EPM 5-8 min post-injection. The results are shown in 
Figure 4-20. One-way ANOVA with dose as independent variable revealed no 
significant effect of CDP microinjection on the dependent variables of % O.A. Time, % 
O.A. Entry, Head Dips and Distance traveled on the EPM, Fs(2, 16) < 1.91, ps > 0.1. A 
total of 19 mice were included in this experiment (Veh, n=7; 10µg/µL, n=6; and 
20µg/µL, n=6). 
 
 
Intra-BLA Microinjection of CDP to α3(H126R) Mice  
 
 To assess the anxiolytic-like effects of CDP within the BLA in mice expressing 
the BZ-insensitive α3-subtype, α3(H126R) mice were given bilateral intra-BLA 
microinjections of CDP at one of the following doses: 10µg/µL, or 20 µg/µL in 0.3uL 
volume. Mice were tested on the EPM 5-8 min post-injection. The results are shown in 
Figure 4-21. One-way ANOVA with dose as independent variable revealed significant 
effects of CDP microinjection on the dependent variables of Head Dips, and Distance 
traveled on the EPM, Fs(2, 20) > 4.11, ps < 0.05. No significant effect was found on the 
dependent variables of % O.A. Time and % O.A. Entry. Dunnett’s test revealed that CDP 
exerted significant anxiolytic-like and motor-stimulating effects as measured by 
significantly increased Head Dips and Distance traveled on the EPM at 20 µg/µL dose 
when compared to vehicle group (ps < 0.05). A total of 23 mice were included in this 
experiment (Veh, n=9; 10µg/µL, n=5; and 20µg/µL, n=9).  
 
 
Intra-BLA Microinjection of Non-Selective CDP – Other Parameters 
 
 Besides the parameters reported in the figures, descriptive statistics were obtained 
for several other parameters, including the distance traveled on the open arm and closed 
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm 
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center 
Time) during the EPM experimentation, are summarized in Table 4-4.  
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Figure 4-20. Intra-BLA Microinjection of CDP in α2(H101R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM.  
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Figure 4-21. Intra-BLA Microinjection of CDP in α3(H126R) Mice 
 
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated 
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B): 
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the 
animal extended its head over the edge of the open arm (Head Dips). (D): total distance 
traveled on the EPM. Asterisks represent significant differences between the vehicle 
injected control group and the drug injected experimental groups as assessed by ANOVA 
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p < 
0.05; **p < 0.01.  
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Table 4-4. Intra-BLA Microinjection of Non-Selective CDP – Descriptive 
Statistics of Other Parameters 
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CHAPTER 5.    DISCUSSION 
 
 
Summary of Findings 
 
 The goal of this study was to further discern the contributions of different α-
subtype GABAARs to BZ-induced anxiolysis based on current existing knowledge. To 
accomplish this, we examined the anxiolytic-like effects of various subtype selective and 
non-selective GABAAR PAMs given to WT C57BL/6J mice and point mutant mice that 
express BZ-insensitive α1-, α2-, or α3-subtype GABAARs. Because the BLA is known as 
a brain region that plays a pivotal role in mediating anxiety-like effects of BZs (M. Davis, 
2000; Green & Vale, 1992; Heldt & Ressler, 2006; Pesold & Treit, 1995; Sanders & 
Shekhar, 1995), we also examined anxiolytic-like effects of intra-BLA microinjections of 
GABAAR PAMs in WT mice as well as point mutant mice. 
 
 
The Effects of Systemic Injection of Selective GABAAR PAMs  
 
 In the experiment using systemic injection of selective drugs, we found that 
selective positive modulation of α1-subtype GABAARs by zolpidem produced mild 
anxiolytic-like effects in WT mice. The dose response relationships were in the form of 
inverted-U shape functions for the measurements of anxiety-like behaviors. Specifically, 
an increase of % O.A. Entry could be observed at doses of 0.5mg/kg and 1mg/kg. 
Systemic administration of zolpidem also produced a dose-dependent inhibition of motor 
activities, and resulted in pronounced motor-inhibiting effects at higher does (1mg/kg and 
2mg/kg). This is in sharp contrast to the result obtained from α1(H101R) mice, where no 
effect on neither anxiety-like measurements nor motor activity was observed, suggesting 
the effects seen in WT mice were indeed mediated by the α1-subtype GABAARs.  
 
 Selective positive modulation of α2-, α3-, (and α5-) subtype GABAARs by 
systemic injection of L-838417 (0.5mg/kg and 2mg/kg) produced profound anxiolytic-
like effects in WT mice as indicated by increases in % O.A. Time, % O.A. Entry and 
Head Dips. These effects were accompanied by motor-stimulating effects at both doses 
tested. On the contrary, selective positive modulation of α2-, (and α5-) subtype 
GABAARs by systemic injection of L-838417 to α3(H126R) mice elicited no statistically 
significant effects on the main measurements of anxiety-like behaviors or motor activity, 
suggesting that the α3-subtype GABAARs are responsible for mediating a significant 
portion of the effects of L-838417 in the EPM paradigm. These findings were in line with 
a previous study showing the anxiolytic-like effects of L-838417 were left intact in 
α2(H101R) mice in a conditioned emotional response test (Morris et al., 2006), signifying 
the contribution of α3-subtype GABAARs. However, one-way ANOVA of the 
measurements related to the animal’s activity on the distal open arm (D.O.A.), such as 
D.O.A. Time and D.O.A. Entry, detected significant anxiolytic-like effects of L-838417 
in α3(H126R) mice, Fs(2, 22) > 4.03, ps < 0.05. Post hoc Dunnett’s tests revealed the 
effects were only seen at the high dose of 2mg/kg, ps < 0.05. This suggested that the 
involvement of α2-subtype in mediating L-838417 induced anxiolysis should not be 
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overlooked. Taken together, we conclude that both α3-, and to a lesser extent, α2-subtype 
GABAARs contribute to the anxiolytic-like effects of L-838417 at doses tested.  
 
 Selective positive modulation of α3-subtype GABAARs by systemic injection of 
TP003 (0.5mg/kg and 2mg/kg) produced profound anxiolytic-like effects in WT mice at 
both doses tested. Motor-stimulating effects at 0.5mg/kg dose were also observed. 
Importantly, the anxiolytic-like effects of systemic TP003 injection were completely 
abolished in α3(H126R) mice. In contrast, TP003 retained its anxiolytic-like effects in 
α2(H101R) mice, suggesting the anxiolytic-like effects of TP003 were indeed mediated 
by α3-, but not α2-subtype GABAARs. Interestingly, TP003 exerted motor-stimulating 
effects in α3(H126R) mice, suggesting that (i) the motor-stimulating effects of TP003 
were not mediated entirely by the α3-subtype GABAARs, and (ii) the anxiolytic-like 
effects of TP003 in WT mice were not simply due to heightened locomotor activities.  
 
 Together, our results suggested that (i) systemic positive modulation of the α1-
subtype GABAARs exerted anxiolytic-like effects at certain doses, however, the 
“therapeutic window” was narrow and the dose for anxiolysis overlapped with the dose 
for motor-impairment; (ii) systemic positive modulation of the α2-, α3-, (and α5-) 
subtype GABAARs exerted anxiolytic-like effects and motor-stimulating effects, and 
such effects were weakened in α3(H126R) mice; and (iii) systemic positive modulation 
of the α3-subtype GABAARs exerted anxiolytic-like effects which were accompanied by 
motor-stimulating effects, although the exact molecular substrates for the motor-
stimulating effects remained unclear. 
 
 
The Effects of Systemic Injection of the Non-Selective CDP 
 
 To extend a previous study (K. S. Smith et al., 2012) that investigated the effect 
of CDP in male point mutant mice and to explore the potential sex differences in animals’ 
response to BZ-induced anxiolysis, both males and females are used in this experiment. 
In the experiment of systemic injection of non-selective CDP, we found that although 
males and females generally showed little differences in terms of their response to drug 
treatment, some discrepancies do exist. Systemic injection of CDP elicited significant 
anxiolytic-like effects in both male and female WT C57BL/6J mice as well as α1(H101R) 
mice. Systemic injection of CDP produced no anxiolytic-like effects in male α2(H101R) 
mice, or in female α2(H101R) mice. Interestingly, in our experiment, systemic injection 
of CDP produced no statistically significant anxiolytic-like effects in male α3(H126R) 
mice, although in female α3(H126R) mice the anxiolytic-like effects were present. These 
results indicated that the anxiolytic-like effects of systemic CDP injection were left intact 
when α1-subtype GABAARs were mutated, however, the anxiolytic-like effects were 
weakened when α2-, as well as α3-subtype GABAARs were mutated, suggesting that (i) 
the α1-subtype GABAARs are dispensable for BZ-induced anxiolysis, and (ii) both the 
α2- and α3-subtype GABAARs are needed for BZ to exert its full effects in inducing 
anxiolysis.  
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The Effects of Intra-BLA Microinjection of Selective GABAAR PAMs 
 
 In the experiment with intra-BLA microinjection of selective drugs, we found that 
selective positive modulation of α1-subtype GABAARs by zolpidem within the BLA 
produced an anxiolytic-like effect at 0.1μg/μL dose, but not other doses tested. Similar to 
the systemic injection result, the dose response curves were in the form of inverted-U 
shape functions for the measurements of anxiety-like behaviors, although no motor 
inhibition or stimulation was observed. Selective positive modulation of α2-, (and α5-) 
subtype GABAARs via intra-BLA microinjection of L-838417 in α3(H126R) mice 
produced anxiolytic-like effects at 0.5μg/μL dose with no significant effect on motor 
activity. Selective positive modulation of α3-subtype GABAARs via intra-BLA 
microinjection of TP003 produced anxiolytic-like effects at 0.25μg/μL and 0.5μg/μL 
doses, and again, the impact on motor activity was minimal. Together, our results 
suggested that (i) intra-BLA microinjection of subtype selective drugs produced similar 
behavioral outcomes when compared to systemic injections in terms of anxiety-like 
behaviors; (ii) intra-BLA microinjection of subtype selective drugs generally produced 
little impact on motor activities; and (iii) BLA is critically involved in mediating the 
anxiolytic-like effects but not the locomotor effects of the subtype selective drugs.  
 
 
The Effects of Intra-BLA Microinjection of Non-Selective CDP 
 
 In the experiment with intra-BLA microinjection of the non-selective CDP, our 
findings were unanticipated in light of previous studies that showed intra-BLA 
microinjection of midazolam and CDP produces anxiolytic-like effects as measured by 
the EPM and open field test (McNamara & Skeleton, 1993; Menard & Treit, 1999; 
Pesold & Treit, 1995). Unexpectedly, no statistically significant anxiolytic-like effect 
were found when CDP was microinjected to the BLA of WT, α1(H101R), or α2(H101R) 
mice. Anxiolytic-like effects could be observed when CDP was microinjected to the BLA 
of α3(H126R) mice, and were accompanied by an unexpected motor-stimulating effects, 
suggesting that the BLA is involved in certain aspects of the anxiolytic-like and motor-
stimulating effects of the non-selective BZ drug CDP.  
 
 
Interpretation of Results 
 
 Although the EPM is a standardized behavioral paradigm to assess anxiety-like 
behaviors in rodents, the actual design of the EPM apparatus and the testing conditions 
are far from uniform across different laboratories. Variations could arise from a number 
of discrepancies such as the opacity of the maze walls, the size of the testing room, and 
the illumination condition (Violle, Balandras, Le Roux, Desor, & Schroeder, 2009). This 
inevitably makes direct comparison between results obtained from studies using different 
testing conditions somewhat problematic. In this study, we used the same EPM apparatus 
in a standard behavioral testing room with controlled lighting condition to minimize test 
variations, which allowed reliable comparison of test scores across different experiments.   
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 The results obtained in the experiments with systemic injection of selective drugs 
were generally in line with previous studies. Systemic positive modulation of the α1-
subtype GABAARs by zolpidem exerted mild anxiolytic-like effects at certain doses. 
However, the “therapeutic window” was narrow and the dose for anxiolysis overlapped 
with the dose for motor-inhibiting effects. This is in line with a previous study that 
reported similar findings in rats (Griebel, Sanger, & Perrault, 1996), and is in keeping 
with another study that suggested the involvement of α1-subtype in anxiety (Belzung et 
al., 2000). However, from a pharmacological point of view, the narrow therapeutic 
window would severely limit the application of zolpidem as a systemic anxiolytic drug. 
Systemic positive modulation of the α2-subtype GABAARs by injection of L-838417 in 
α3(H126R) mice exerted minimal anxiolytic-like effects at doses tested as revealed by 
non-significant statistical results on the main measurements of anxiety-like behaviors, 
which appeared much weaker than the effects of L-838417 found in WT mice. However, 
parameters related to the animal’s activity on the D.O.A. revealed some residue 
anxiolytic-like effects of L-838417 in α3(H126R) mice. This suggests that the α2-subtype 
GABAARs, previously thought to play a pivotal role in mediating BZ-induced anxiolysis 
(Low et al., 2000; K. S. Smith et al., 2012), were in fact partially involved in mediating 
the anxiolytic-like effects elicited by L-838417 at doses tested. Systemic positive 
modulation of the α3-subtype GABAARs by injection of TP003 in WT mice exerted 
anxiolytic-like effects. This is also in keeping with the previous finding (Atack et al., 
2005; Dias et al., 2005; Fischer et al., 2011) that suggested the involvement of α3-
subtype in anxiety. Our data also revealed a motor-stimulating effects induced by 
systemic injection of TP003. However, systemic TP003 treatment retained its motor-
stimulating effects in α3(H126R) mice, whereas the anxiolytic-like effects were 
completely abolished. This suggests the motor-stimulating effect of TP003 might not be 
entirely mediated by the α3-subtype GABAARs.  
 
 In line with previous studies (K. S. Smith et al., 2012), systemic positive 
modulation of the α1-, α2-, α3-, (and α5-) subtype GABAARs by injection of CDP in WT 
mice exerted anxiolytic-like effects in males. Similar effects were also observed in 
female WTs. The anxiolytic-like effects were preserved in both male and female 
α1(H101R) mice. Of note, for female subjects, the 5mg/kg dose elicited no significant 
anxiolytic-like effects in WTs, whereas the same dose elicited prominent anxiolytic-like 
effects in α1(H101R) mice, suggesting the anxiolytic-like effects of CDP was not only 
preserved, but also potentiated in female mice lacking BZ-sensitive α1-subtype 
GABAARs. Expectedly, both male and female α2(H101R) mice were generally 
insensitive towards the anxiolytic-like effects of systemic CDP injection. Surprisingly, 
systemic injection of CDP elicited no significant anxiolytic-like effects in male 
α3(H126R) mice, which was in contrast with a previous report (K. S. Smith et al., 2012). 
On the other hand, female α3(H126R) mice remained sensitive toward CDP induced 
anxiolysis. To sum up, (i) for males, the anxiolytic-like effects of BZ were unaffected in 
α1(H101R) mice, and reduced in α2(H101R) as well as α3(H126R) mice, suggesting both 
α2- and α3-subtypes were crucially involved, and α1-subtype GABAARs were 
dispensable, (ii) for females, the anxiolytic-like effects of BZ were potentiated in 
α1(H101R) mice, reduced in α2(H101R) mice and preserved in α3(H126R) mice, 
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suggesting that only α2-subtype GABAARs were crucially involved, while α1- and α3-
subtypes were dispensable.  
 
 The sex differences observed suggested that female mice were generally more 
resilient in terms of their sensitivity towards BZ-induced anxiolysis when a particular α-
subtype is mutated. Sex differences in GABAergic signaling were supported by various 
studies in human as well as in animals. For example, a previous study showed that the 
availability of BZ-sensitive GABAAR in women was higher when compared to men 
(Esterlis et al., 2013). In rodents, one study showed that the expressions of α1- and α3-
subtype GABAARs in the anterior substantia nigra pars reticulata were higher in females 
than males at postnatal day 5 (Chudomel, Herman, Nair, Moshe, & Galanopoulou, 2009). 
However, other studies revealed no drastic sex differences in the expression of α1-, α2-, 
or α5-subunit (A. M. Davis, Penschuck, Fritschy, & McCarthy, 2000; Nett, Jorge-Rivera, 
Myers, Clark, & Henderson, 1999). These findings, although ambiguous, offered a 
possible rationale that sex differences in GABAAR expression level could explain why 
female mice might be more likely to retain sensitivity to BZ-induced anxiolysis when a 
particular α-subtype was rendered BZ-insensitive than their male counterparts. Future 
experiments addressing the sex-differences of GABAAR expression in the BLA and the 
response towards BZ-induced anxiolysis in rodents would be of great interest.  
 
 Currently, the effect of intra-BLA microinjection of selective drugs is poorly 
understood. Our results revealed that selective intra-BLA positive modulation of α1-, α2-, 
or α3-subtype GABAARs produced similar anxiolytic-like behavioral outcomes when 
compared to systemic positive modulation. This suggested that BLA is indeed a critical 
brain region which is sufficient to mediate the anxiolytic-like effects, but not the motor-
inhibiting or stimulating effects of the subtype selective GABAAR PAMs.  
 
 The result obtained from the intra-BLA microinjection of CDP experiment was 
somewhat difficult to interpret. CDP elicited no pronounced anxiolytic-like effects in 
WT, α1(H101R) or α2(H101R) mice, when administered directly to the BLA. This is in 
contrast to previous studies that showed intra-BLA microinjection of CDP and 
midazolam elicited anxiolytic-like effects in the EPM test or open field test in rodents 
(McNamara & Skeleton, 1993; Menard & Treit, 1999; Pesold & Treit, 1995). The 
observed phenomena might be sensitive to the test conditions, i.e., due to the lighting 
condition and the particular construction of the EPM used in our experiment that had 
transparent plexiglass walls around the closed arm, rather than opaque or wooden ones 
used in many other studies. These particular factors were known to affect the animal’s 
behavior on the EPM (Violle et al., 2009). Another possible explanation is that since 
GABAARs are known to be differentially expressed on different populations of 
GABAergic interneurons (Baude, Bleasdale, Dalezios, Somogyi, & Klausberger, 2007; 
Milenkovic et al., 2013), the augmentation effects of PAMs, including CDP, on the 
GABAAR may not be restricted to the projection neurons. It is possible that application of 
CDP locally would cause inhibition of certain population of GABAergic interneurons, 
and subsequently result in reduced GABA release from those neurons which might 
further cancel out the potentiation of the inhibitory effects exerted by CDP on the 
projection neurons. Molecular and functional characterization of the GABAARs 
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expressed on the GABAergic interneurons within the BLA would be of great value to 
help better understand the properties of the GABAergic microcircuitries and their 
functions in the context of fear and anxiety. A third possibility is that under certain 
circumstances, GABA signaling might actually be excitatory rather than inhibitory. A 
recent study suggested that a subpopulation of parvalbumin positive interneurons could 
synchronize the activity of a group of pyramidal neurons via GABAergic excitation 
within the BLA (Spampanato, Sullivan, Perumal, & Sah, 2016). It is thus also likely that 
BZ-induced augmentation of GABAARs might increase the synchronizing effect of the 
parvalbumin positive interneurons and subsequently enhance the BLA net output. Further 
studies that focus on addressing the alteration of intra-BLA GABAergic microcircuitries 
under the influence of CDP will benefit the understanding of the paradoxical effects seen 
here in the intra-BLA CDP microinjection experiment. 
 
 
Limitations of Experimental Design and Results 
 
 As mentioned above, the EPM test is a locomotion-dependent behavioral 
paradigm and the measurements of anxiety should be examined with care when a motor-
inhibiting or stimulating effects are present (Reynolds et al., 2001). However, the use of 
entry ratios (% O.A. Entry), rather than the raw numbers of O.A. entry, should help to at 
least reduce the bias introduced by locomotion differences amongst different groups. 
Future experiments employing locomotion-independent anxiety tests, such as stress-
induced hyperthermia, would be beneficial for this matter.  
 
 In this study, only one brain region, i.e. the BLA, is investigated. As previously 
mentioned, the BNST and hippocampus are two other main brain regions known to play a 
role in anxiety-like behaviors (Engin & Treit, 2007b; Gafford et al., 2012). Future studies 
investigating the anxiolytic-like effects of intra-BNST and intra-hippocampus 
microinjection of selective and non-selective GABAAR PAMs in WT and point mutant 
mice would be of great importance in pinpointing the regional specific roles the 
GABAAR α-subtypes play in mediating BZ-induced anxiolysis. 
 
 
Conclusion and Clinical Significance 
 
 In an attempt to unify the current debate concerning “which GABAAR α-subtype 
contributes to BZ-induced anxiolysis”, this study incorporates both subtype selective 
GABAAR PAM and α-subunit point mutant mice to finely dissect the functional roles 
played by α1-, α2-, and α3-subtype GABAARs in mediating anxiety-like behaviors and 
anxiolysis-like effects. In general, our findings support the conclusion that both α1-, α2-, 
and α3-subtype GABAARs are involved in mediating anxiety-like behaviors. However, 
subtle differences do exist. Positive modulation of α1-subtype GABAARs exerts 
anxiolytic-like effects with a narrow therapeutic window that overlaps with the dose for 
motor-inhibiting effects. In contrast, positive modulation of α2-, α3- (and α5-) subtype 
GABAARs exerts significant anxiolytic-like and motor-stimulating effects. These effects 
are weakened in the absence of BZ-sensitive α3-subtypes. Positive modulation of the α3-
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subtype GABAARs exerts anxiolytic-like effects that are accompanied by significant 
motor-stimulating effects. Lack of either BZ-sensitive α2-, or α3-subtype GABAARs 
weakened the anxiolytic-like effects of CDP in a sex-dependent manner. Together, our 
findings sufficiently addressed the currently debatable view of the role played by the α3-
subtype GABAARs in BZ-induced anxiolysis.  
 
 We have also extended the current understanding of the differential roles played 
by α1-, α2-, and α3-subtype GABAARs on anxiety-like behaviors from the systemic level 
to a specific brain area, the BLA. Our data clearly indicates that the anxiolytic-like effects 
of selective intra-BLA positive modulation of α1-, α2-, and α3-subtype GABAARs are 
largely similar to the systemic positive modulation, in absence of the impact on motor 
activities. The non-selective positive modulation of GABAARs in the BLA results in 
minimal, unclear effects on anxiety measures, which might be explained by a complex 
inhibition / disinhibition balance between the GABAARs expressed on the projection 
neurons versus the GABAARs expressed on the inhibitory interneurons under the 
influence of non-selective BZs within the BLA.  
 
 Our results suggest that α3- and/or α2-subtype selective GABAAR PAMs, such as 
TP003, could be prime candidates for developing selective anxiolytic drugs. The motor-
stimulating effects found in systemic TP003 treatment should be further investigated to 
identify the exact molecular substrate mediating such effects. Our results also suggest 
that novel α2-subtype selective GABAAR PAMs would be of great value for both 
developing anxiolytic drugs, and for advancing the investigation of the differential 
functional roles played by different GABAAR α-subtypes in the brain.  
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